

A TEXTBOOK OF PATHOPHYSIOLOGY

ISBN: 978-81-985724-1-7

A TEXT BOOK OF

Pathophysiology

(As Per PCI Syllabus For B. Pharm II Sem)

Dr Arpan K Tripathi



DOI 10.5281/zenodo.15399027

Chapter- 1

Fundamentals of Cellular Injury, Adaptation, and Inflammation

DR. SARFARAZ AHMAD

Assistant Professor,
Department of Clinical Practice, Pharmacy
Practice Research Unit (PPRU), College of
Pharmacy, Jazan University, Postal Code:
45142; Saudi Arabia, KSA.
Email- sriyazahmad@jazanu.edu.sa

DR G CHANDRA SEKHRA RAO

Professor,
Vigan Institute of Pharmaceutical
Chemistry
Besides VSEZ Vadlapudi Duvvada,
Gajuwaka, Visakhapatnam, Andhra Pradesh
530049
Email- gonuguntac2@gmail.com

DR DILIP KUMAR GUPTA

Professor,
Raj Kumar Goel Institute of Technology,
Pharmacy
5KM Stone Delhi, Meerut Rd, near Raj
Nagar Extension, Ghaziabad, Uttar Pradesh
201017
dilipfph@rkgit.edu.in

DR. MOIDUL ISLAM JUDDER

Assistant Professor,
Royal School of Pharmacy, The Assam
Royal Global University, Betkuchi, Opp.
Tirupati Balaji Temple, NH 37, Guwahati -
781035, Assam, India
Email - moonzodder@gmail.com

DR. RAKIBUR RAHMAN

Assistant Professor,
Royal School of Pharmacy, The Assam
Royal Global University, Betkuchi, Opp.
Tirupati Balaji Temple, NH 37, Guwahati -
781035, Assam, India
Email - rakiburrahman105@gmail.com

Unit 1...

FUNDAMENTALS OF CELLULAR INJURY, ADAPTATION, AND INFLAMMATION

DR. SARFARAZ AHMAD

Assistant Professor

Department of Clinical Practice, Pharmacy Practice Research Unit (PPRU), College of
Pharmacy, Jazan University, Postal Code: 45142; Saudi Arabia, KSA.

Email- sriyazahmad@jazanu.edu.sa

DR G CHANDRA SEKHRA RAO

Professor

Vigan Institute of Pharmaceutical Chemistry

Besides VSEZ Vadlapudi Duvvada, Gajuwaka, Visakhapatnam, Andhra Pradesh 530049

Email- gonuguntac2@gmail.com

DR DILIP KUMAR GUPTA

Professor

Raj Kumar Goel Institute of Technology, Pharmacy

5KM Stone Delhi, Meerut Rd, near Raj Nagar Extension, Ghaziabad, Uttar Pradesh 201017

dilipfph@rkgit.edu.in

DR. MOIDUL ISLAM JUDDER

Assistant Professor

Royal School of Pharmacy, The Assam Royal Global University, Betkuchi, Opp. Tirupati
Balaji Temple, NH 37, Guwahati - 781035, Assam, India

Email - moonzodder@gmail.com

DR. RAKIBUR RAHMAN

Assistant Professor,

Royal School of Pharmacy, The Assam Royal Global University, Betkuchi, Opp. Tirupati
Balaji Temple, NH 37, Guwahati - 781035, Assam, India

Email - rakiburrahman105@gmail.com

1.1 Basic Principles of Cell Injury and Adaptation

1.1.1 Introduction

Cells, which are the fundamental units of life, are constantly subjected to a wide variety of stressors and changes in their environment, which constitute a threat to their structural and functional integrity. When it comes to the survival of an organism, the capacity of a cell to both keep homeostasis and adapt to the various difficulties that it faces is absolutely essential. When confronted with unfavorable circumstances, cells react by activating a number of adaptive mechanisms with the purpose of retaining their functionality and preventing damage that cannot be reversed. Nevertheless, injury takes place when the stress surpasses the adaptive ability of the cell, which might result in the death of the cell if the damage is substantial or if it continues for an extended period of time.




Figure 1: Cell Injury and suicide

Cell damage can be caused by a variety of factors, including physical ones (e.g., trauma, extreme heat or cold, radiation), chemical ones (e.g., toxins and drugs), infectious ones (e.g., bacteria, viruses, or fungi), immunologic reactions, genetic abnormalities, nutritional imbalances, or oxidative stress. Numerous more elements can also induce cell damage. These variables can disturb cellular homeostasis because they impede important cellular processes such energy production, membrane integrity maintenance, protein synthesis, and DNA repair.

The cell's ability to react to the stressor, the kind of stress, and the length of time it lasts all play a role in determining the kind and degree of damage that the cell experiences.

Cellular adaptation entails alterations to cellular structure, function, and metabolism brought on by environmental changes. We equate adaptation with the phrase "adaptation." Several alterations to cells might take place as a result of this, such as hypertrophy (cell size increase), hyperplasia (cell number rise), atrophy (cell size decrease), and metaplasia (cell type substitution). Removing or reducing the stress can often undo these adaptive adaptations. However, if the cell is unable to adjust to the stress or if the stress continues, it may experience irreversible damage, which can result in necrosis (the death of cells without control) or apoptosis (the death of cells according to a predetermined plan).

To have a complete understanding of the pathophysiology of a variety of diseases, it is necessary to have a fundamental understanding of the fundamental principles of cell injury and adaptation. It offers a glimpse into the ways in which cells deal with stress and what occurs when their adaptive processes are unable to function properly. This information is essential in the disciplines of pathology, medicine, and biomedical research since it serves as the foundation for the development of therapeutic strategies that are targeted at preventing or minimizing cell harm, as well as increasing cell survival and recovery. The investigation of cellular injury and adaptation not only contributes to the determination of the factors that lead to the development of diseases, but it also assists in the creation of therapies that can improve clinical outcomes and promote cellular resilience.

1.1.2 Definitions

The essential processes that cells go through in order to react to both internal and external stimuli are included in the fundamental principles which govern cell damage and adaptation. When it comes to understanding how cells keep their homeostasis, how they adapt to changes in their environment, and what occurs when they are unable to cope with stress, which can lead to injury or death, these principles are absolutely essential. The term "cell injury" refers to the adverse changes that take place in cells as a result of their exposure to harmful stimuli. These stimuli can include physical trauma, chemical agents, pathogenic organisms, or environmental stresses such as hypoxia. Not only does the origin, duration, and intensity of the insult have a role in determining the level of cell injury, but also the type of cell and its capacity to adapt to new circumstances. Cells are typically able to recover after the detrimental stimulus has been withdrawn, even if the injury is quite minor or only temporary. On the other hand, if the injury

is severe or continuous, it may result in damage that cannot be reversed, which ultimately leads to the death of cells. The disruption of energy production, the loss of membrane integrity, the impairment of protein synthesis, and the damage to DNA are the key mechanisms that are responsible for cell impairment.

On the other hand, the term "cell adaptation" refers to the mechanisms that allow cells to adjust their structure and function in response to changes in their surrounding environment. It is because of this adaptive reaction that cells are able to survive and continue to operate normally under a wide range of situations. Hypertrophy, hyperplasia, atrophy, and metaplasia are the several types of cellular adaptation that are most commonly seen. In contrast to hyperplasia, which is defined by a rise in cell number due to higher proliferative ability, hypertrophy is characterized by an increase in cell size, which typically occurs in response to an increase in the volume of functional demand. Metaplasia is a reversible shift that occurs when one differentiated cell type is replaced by another that is more adapted to endure the stress. Atrophy is a process that occurs when cells shrink in size as a result of diminished functional demand or bad conditions. A thorough familiarity with these cornerstone concepts is crucial for any pathologist wishing to understand how diseases manifest at the cellular level. By learning how cells respond to stress and damage, doctors and other medical professionals can enhance their capacity to detect, cure, and avoid numerous illnesses and conditions. When it comes to health, maintaining a healthy equilibrium between cell injury and adaptability is essential, and any changes in this equilibrium can result in substantial pathological repercussions.

1.1.3 Homeostasis

The process by which living organisms are able to keep their internal environments consistent in spite of changes in their external environments is known as homeostasis. Every single biological system, from simple organisms with a single cell to complex multicellular entities like humans, relies on this notion to work properly. Several physiological parameters, including as electrolyte balance, glucose levels, pH, and temperature, are regulated throughout homeostasis. That way, the body's internal environment can stay within certain parameters that promote health and vitality.




Figure 2: Homeostasis

When it comes to maintaining the structural integrity and functional capacity of individual cells, homeostasis is an essential component at the cellular level. At all times, cells are subjected to alterations in their external environment, which may include shifts in the availability of nutrients, variations in oxygen levels, and the presence of dangerous substances. The cells have developed complex regulatory mechanisms that enable them to adapt and keep their internal equilibrium in order to deal with the changes that are occurring. For instance, in order to control osmotic pressure and prevent cellular swelling or shrinking, cells regulate the passage of ions across their membranes for the purpose of regulating them. Additionally, they regulate metabolic pathways in order to generate energy in an effective manner under a variety of settings. This helps to guarantee that ATP levels continue to be sufficient to support cellular activity.

In addition to encompassing individual cells, the concept of homeostasis encompasses tissues, organs, and even entire systems that are found within the body. An example of this would be how the human body is able to keep its core temperature stable by striking a balance between the production of heat and the loss of heat. A number of mechanisms, including shivering and vasoconstriction, are engaged in response to a decrease in the temperature of the environment. These mechanisms create heat and conserve heat, respectively. Sweating and vasodilation, on

the other hand, provide assistance in dissipating heat and preventing overheating as the temperature of the environment increases. In a similar manner, the endocrine system is responsible for controlling hormone levels, which in turn effect the metabolism, growth, and stress responses of the body. This system plays a significant part in the maintenance of homeostasis.

The use of effectors, control centers, and sensors in feedback systems allows for the maintenance of homeostasis. The regulation of blood glucose levels is one well-known example. When blood glucose levels rise after eating, insulin is secreted by the pancreas. The action of insulin is to lower blood glucose levels by enhancing cellular absorption of glucose. The pancreas secretes glucagon in response to low blood glucose levels, which triggers the release of glucose from the liver's glycogen stores. This process brings glucose levels back to normal. Through the use of this feedback loop, blood glucose levels are maintained within a range that satisfies the body's requirements for energy without risking any adverse effects.

It is possible for disease and dysfunction to result from a disruption of homeostasis. For instance, diabetes mellitus is characterized by an impairment in the homeostatic regulation of blood glucose, which results in persistently elevated blood sugar levels. This, in turn, can lead to damage to organs and tissues over the course of time. In a similar vein, the breakdown of homeostatic systems in the regulation of temperature can lead to conditions such as hypothermia or hyperthermia, both of which have the potential to be fatal.

1.1.4 Components and Types of Feedback Systems

In biological systems, feedback systems are among the most important mechanisms that contribute to the maintenance of homeostasis. Their operation is based on the monitoring of physiological parameters and the implementation of any necessary adjustments in order to maintain these parameters within a stable range. There are normally three primary components that make up a feedback system. These components include effectors, sensors, and a control center. The internal environment is monitored by these components, which operate in concert with one another to identify any changes that may occur and then initiate the proper responses in order to regain equilibrium.

❖ Feedback System Components and Components

The ability to detect changes in one's internal or external surroundings is a hallmark of sensitive cells and structures. Receptors are another name for sensors. They are tasked with keeping an

eye on specific parameters like pH, temperature, blood pressure, or glucose levels, and relaying that data to the command center. As the first line of defense in the feedback system, sensors are responsible for ensuring that any deviation from the usual range is identified as soon as possible.

Control Center: The control center, which is often situated in the area of the brain or the endocrine glands, is responsible for processing the information that is received from the sensors. It makes a comparison between the value that was detected and a set point, which is the value that is intended or considered typical for the variable that is being monitored. The control center will launch a response by sending signals to the effectors at the beginning of the process if the detected value is different from the set point. Within the context of the feedback loop, the control center serves as the decision-maker, selecting the specific response that is required to keep homeostasis stable.

The organs, tissues, or cells that are responsible for carrying out the response that was initiated by the control center are referred to as effectors. They take action to correct the departure from the fixed point after receiving signals from the control center and acting on those signals. Some examples of actions that muscles, glands, or other organs may be involved in include raising or reducing the number of hormones that are secreted, modifying the flow of blood, or changing the activity of the metabolic system. To finish off the feedback loop, effectors are responsible for bringing about the essential adjustments that are required to return the variable to its normal range.

❖ Varieties of Feedback Technologies

Feedback systems can be divided into two primary categories: those that provide negative feedback and those that provide positive feedback. In the process of regulating physiological processes and preserving homeostasis, each kind fulfills a function that is individually distinct.

When it comes to feedback systems, the most prevalent type seen in biological creatures is known as negative feedback. When negative feedback is present, the response that is produced by the effectors works as a counterbalance to the initial stimulus, which in turn reduces the amount of deviation from the set point. This particular form of feedback is effective in preserving stability by reversing changes that cause the system to move away from equilibrium.

The control of core body temperature is a paradigmatic example of negative feedback in action. When the body's temperature rises above a certain point, sensors in the hypothalamus and the

skin detect the change and communicate this information to the hypothalamic control center. Effectors, such as sweat glands, are then activated by the control center, which causes an increase in sweating and causes blood vessels to widen, which in turn promotes heat loss. As the body cools down and returns to the set point, the feedback loop becomes less effective, which prevents the body from cooling down any further.

The significance of negative feedback systems lies in the fact that they neutralize disruptions and preserve physiological variables within a restricted and stable range. This makes them an essential component in the process of homeostasis maintenance. A number of processes, including the regulation of blood glucose, the management of blood pressure, and the secretion of hormones, are influenced by them.

Beneficial Feedback: Beneficial feedback amplifies the initial stimulus, which in turn leads to an even more significant reaction from the effectors. In contrast to negative feedback, positive feedback does not serve to preserve equilibrium; rather, it is responsible for driving processes to their intended conclusion. The body is not particularly good at providing positive feedback, yet it is absolutely necessary in specific circumstances where a prompt or definitive outcome is required.

Take, for instance, the process of giving birth, which is widely recognized as one of the most prominent examples of positive feedback. Oxytocin is released from the pituitary gland when the cervix is stretched during childbirth. This causes the pituitary gland to generate more of the hormone. The uterine contractions that are triggered by oxytocin cause the cervix to be stretched even farther, which in turn causes the production of further oxytocin. This cycle continues, with contractions increasing stronger and more frequent, until the baby is born, at which point the positive feedback loop is broken. Until then, the baby is born.

The importance of providing positive feedback lies in the fact that it is essential in procedures that call for a swift increase in activity or a distinct conclusion. In processes like blood clotting, where a single injury triggers a cascade of reactions that culminate in the formation of a clot, it plays a crucial role. Aside from stopping further bleeding, this clot also closes the wound.

1.1.5 Causes of cellular injury

When cells are subjected to detrimental stimuli that impair their normal function and structure, this may result in the cells suffering from cell damage. These stimuli can originate from a wide variety of sources, including those that are physical, chemical, biological, immunological,

genetic, and dietary in nature. The ability of the cell to maintain homeostasis can be hindered by each of these factors, which can result in damage or death if the injury is severe or if it lasts for an extended period of time.

➤ **Agents of the Physical World**

One of the most prevalent types of agents that might cause damage to cells is physical agents. Radiation, physical stress, and severe temperatures are some examples of these. Direct damage to the cell membranes can be caused by trauma, such as blunt force injuries, wounds, or fractures. This can result in the loss of structural integrity and the leakage of cellular contents. Thermal injuries can be caused by variations in temperature that are excessive, such as heat and cold. By denature proteins, damage cell membranes, and produce coagulative necrosis, heat can cause coagulative necrosis. On the other hand, cold can cause ice crystals to develop inside of cells, which disrupts membrane integrity and ultimately results in cell death. Radioactivity, and more specifically ionizing radiation, has the potential to inflict significant harm to the components of cells, most notably DNA. This can result in mutations, decreased cell division, and, in more severe cases, necrosis or death of the cells.

➤ **Aspects of Chemicals**

Toxins, medicines, and pollutants are all examples of chemical agents that have the potential to cause damage to cells by their interaction with cellular components and disruption of typically occurring metabolic processes. Toxins, such as those that are created by bacteria or that are present in the environment, have the ability to disable essential enzymes, interfere with the metabolic processes of cells, and cause oxidative damage. The use of drugs, whether for therapeutic or recreational purposes, can have a toxic effect on cells, particularly when the drugs are used in excessive amounts or in individuals who are particularly susceptible to their effects. It is possible for pollutants, such as heavy metals and organic compounds, to accumulate in tissues and cause persistent damage. This can be accomplished by producing oxidative stress, interfering with cellular signaling, or causing direct toxicity to the structures of cells.

➤ **The Agents of Infection**

A key contributor to the damage that is done to cells is the presence of infectious organisms, which can include bacteria, viruses, fungus, and parasites. These pathogens have the ability to penetrate cells, take over the machinery of the cell in order to replicate, and create toxins that

cause damage to the structures of the cell. Microorganisms have the ability to generate exotoxins, which interfere with the functioning of cells, as well as endotoxins, which cause inflammatory reactions that result in damage to tissues. It is possible for viruses to cause damage to cells by either directly destroying the DNA of the cells, triggering apoptosis, or causing immune-mediated elimination of the cells that are infected. Cell damage can also be caused by fungi and parasites through direct invasion, the generation of toxic compounds, or the induction of persistent inflammatory responses.




Figure 3: Chain Infection

➤ **Reactions of the Immune System**

Immunologic reactions, such as autoimmune illnesses and hypersensitivity reactions, have the potential to cause considerable damage to cells. A condition known as autoimmune illness occurs when the immune system incorrectly attacks the body's own cells, mistaking them for foreign cells. This results in persistent inflammation and the loss of healthy tissues. For instance, rheumatoid arthritis, in which immune cells assault joint tissues, and lupus, in which

many organs are targeted, are both examples of types of autoimmune diseases. Hypersensitivity reactions, such as allergic reactions, have the potential to induce both acute and chronic inflammation, which can ultimately result in damage to the tissues. In extreme circumstances, such as anaphylaxis, extensive immune activation can lead to cell damage that poses a significant risk to the patient's life.




Figure 4: Immune System

➤ Defects of the Genes

Cell damage can be caused by genetic flaws, which include inherited mutations and genetic predispositions. These defects reduce the normal functioning of cells, which can result in cell damage. It is possible for inherited mutations to have an effect on essential proteins, enzymes, or signaling pathways, which can result in metabolic imbalances, structural deformities, or an increased vulnerability to environmental stresses. For instance, cystic fibrosis is caused by mutations in the gene known as the cystic fibrosis transmembrane conductance regulator (CFTR), which results in the creation of thick mucus, chronic lung infections, and gradual cell damage. In a similar manner, mutations in tumor suppressor genes such as p53 can put cells at risk for uncontrolled development and malignancy.




Figure 5: Defects of the Genes

➤ **Unevenness in Nutritional Needs**

Cell damage can be caused by nutritional imbalances, which can include deficiencies or excesses in vitamins, minerals, and nutrients. These imbalances can disrupt metabolic processes, which can lead to cell damage. Scurvy, rickets, and anemia are all illnesses that can be caused by deficiencies in critical nutrients such as vitamins A, C, and D, as well as iron. These deficiencies can negatively impact the activities of cells. The use of particular nutrients in excessive amounts, such as fats, sugars, or sodium, can result in illnesses such as obesity, diabetes, and hypertension, all of which are known to induce chronic cell harm and organ damage over the course of time. Malnutrition, whether it be due to undernutrition or overnutrition, can have a negative impact on the immune system, hinder the healing process of wounds, and increase the likelihood of contracting infections and other disorders.

➤ **Stress Caused by Oxidation**

Cell damage is caused in part by oxidative stress, which is triggered by an accumulation of reactive oxygen species (ROS). Damage to DNA, proteins, and lipids can be caused by reactive oxygen species (ROS), which are very reactive chemicals. Cells naturally produce reactive oxygen species (ROS) as a metabolic byproduct; however, they also have antioxidant defenses that can neutralize these ROS. When these safeguards are overwhelmed, however, by the production of reactive oxygen species (ROS), oxidative stress develops and cells are damaged.

Protein misfolding, DNA mutations, and lipid peroxidation are all possible byproducts of this process; together, they can disturb cellular function and cause cell death. Numerous diseases have been associated with oxidative stress, including cancer, cardiovascular disease, and neurological disorders like Parkinson's and Alzheimer's.

The sensitivity of cells to a wide variety of damaging stimuli is demonstrated by the causes of cell injury that have been discussed here. There are a number of factors that determine the extent of the damage, including the nature, duration, and intensity of the agent that caused the damage, as well as the capacity of the cell to adapt or heal the harm. In order to develop strategies to avoid or lessen cell injury and to devise effective treatments for diseases that are caused by cellular damage, it is essential to have a solid understanding of these pathways.

1.1.6 Pathogenesis (Cell membrane damage, Mitochondrial damage, Ribosome damage, nuclear damage)

A number of different processes that disturb cellular functioning and integrity are involved in the pathophysiology of cell damage. Deterioration of cell membranes, mitochondria, ribosomes, and the nucleus are the main categories that can be used to classify these mechanisms respectively. One can have a better understanding of how cells react to stress and the factors that contribute to cellular malfunction or death by gaining an understanding of these types of damage.

Cell membrane damage

In order to maintain the cell's integrity and regulate the exchange of substances with its environment, the cell membrane—also called the plasma membrane—is an important structure. The building blocks are proteins that perform multiple functions, including transport, signal transduction, and cell recognition, embedded in a lipid bilayer. In order to maintain the cellular environment and enable vital physiological functions, the selective permeability of the cell membrane is a crucial component. Cell membrane damage is an important step in the pathophysiology of cell injury, and it can be caused by a variety of stimuli. Physical trauma, chemical pollutants, and oxidative stress are all examples of such stressors.




Figure 6: Cell membrane damage

❖ Damage Mechanisms and Risks

One of the initial steps in cell membrane injury is the breakdown of the lipid bilayer, which is mainly composed of phospholipids. The role of reactive oxygen species (ROS) is crucial to this procedure. Examples of reactive oxygen species (ROS) include hydroxyl radicals and superoxide anions. Reactive oxygen species (ROS) are highly reactive molecules that can be either naturally occurring in the body or introduced from external sources. They are created as a result of cellular metabolism. These species cause oxidative damage when they interact with the cell membrane's lipid components, a process known as lipid peroxidation. Lipid peroxidation occurs when reactive oxygen species (ROS) oxidize the membrane's polyunsaturated fatty acids, leading to the formation of unstable lipid peroxides.

The structure of the membrane is further deteriorated by these lipid peroxides, which have the ability to start a chain reaction that ultimately leads to the fragmentation of lipid molecules. Because of this degradation, the membrane's fluidity and integrity are compromised, which results in an increase in the membrane's permeability. Direct damage to the membrane can also be caused by physical trauma or mechanical forces, which can result in ruptures or tears that disturb the membrane's normal function. Toxins can also cause damage to the membrane by interacting with its lipid or protein components, which hinders the membrane's capacity to maintain cellular homeostasis. Heavy metals and certain medicines are examples of chemical toxins that can cause this damage.

❖ The repercussions

There are significant and frequently harmful effects on cellular function that occur when the integrity of the cell membrane is compromised. The increased permeability of the membrane is one of the immediate effects, which makes it possible for potentially dangerous substances, such as ions, poisons, or infections, to enter the cell more easily. Intermittently, it is possible for vital intracellular components, such as ions and proteins, to escape from the cell. This disruption of the internal environment causes ionic imbalances, namely a buildup of calcium ions within the cell, which can activate damaging intracellular enzymes. namely, calcium ions can accumulate inside the cell.

A direct consequence of membrane injury is the development of cellular swelling, sometimes known as edema. The influx of water into the cell, which is driven by osmotic gradients, has the potential to cause the cell to enlarge and even rupture. This swelling causes organelles within the cell to become disorganized and affects the normal activities of the cell. In addition, the lack of membrane integrity is a trigger for a number of other pathways that lead to cell death. Necrosis is a type of uncontrolled cell death that occurs when the membrane of a cell is severely and persistently damaged. This damage causes the cell to lyse and causes inflammation in the tissue that surrounds the cell. Alternately, if the damage is not as severe but continues for an extended period of time, the cell may go through a process known as apoptosis, which is a sort of programmed cell death that takes place when the cellular damage exceeds the capacity of the cell's repair systems.

Damage to the cell membrane that is either significant or persistent might result in irreparable damage, which hinders the cell's capacity to heal and continue to function normally. Damage to membranes can have a cumulative effect, which can lead to a variety of pathological situations. These conditions include inflammation, damage to tissues, and the advancement of diseases such as cardiovascular disorders, neurological diseases, and cancer. In order to create therapeutic techniques that have the potential to alleviate cellular injury and guard against illness, it is essential to have a solid understanding of the mechanisms and consequences of cell membrane damage.

Mitochondrial Damage

Mitochondria are sometimes called the "powerhouses" of the cell because of their crucial function in generating adenosine triphosphate (ATP), the main energy carrier in cells. The

mitochondria use a mechanism called oxidative phosphorylation to create ATP. To accomplish this, electrons must travel via the electron transport chain (ETC) and then be used to fuel the production of ATP from inorganic phosphate and adenosine diphosphate (ADP). The regulation of metabolic processes, protein synthesis, and ion pumping are just a few of the many cellular functions that rely on this mechanism. This essential function is disrupted when mitochondria are damaged, which can result in a variety of clinical diseases.




Figure 7: Mitochondrial Damage

❖ Damage Mechanisms and Risks

The main reason mitochondrial damage occurs is oxidative stress. When the production of reactive oxygen species (ROS) surpasses the cell's ability to neutralize them, oxidative stress is caused. Superoxide anions, hydrogen peroxide, and hydroxyl radicals are examples of reactive oxygen species (ROS) that are typically produced during mitochondrial respiration. The flip side is that ROS can harm proteins, lipids, and mitochondrial DNA (mtDNA) with extended exposure. Proteins encoded by mitochondria are essential for the electron transport system, but mutations caused by DNA oxidation pose a threat to their production. Reduced ATP synthesis and elevated ROS levels are the subsequent consequences of this, exacerbating oxidative stress even further.

Mitochondrial damage can result from oxidative stress or from disruptions to the membrane's potential or permeability, among other potential sources. The maintenance of the electrochemical gradient necessary for ATP synthesis is primarily regulated by the voltage of the mitochondrial membrane. Toxins, ischemia, or metabolic disorders can disturb this gradient, leading to membrane integrity loss and the proton gradient collapsing. Because of this defect, ATP production is impaired, and there's a chance that pro-apoptotic chemicals may leak out of the mitochondria into the cytoplasm.

❖ The repercussions

When mitochondria are damaged, the primary effect that occurs is a dramatic decrease in the amount of ATP that is produced. The production of ATP is essential for practically all cellular operations that are dependent on energy. These processes include the pumping of ions by ATPases, the synthesis of proteins, and the elimination of unhealthy chemicals. These essential tasks are hindered when there is a decline in the amounts of ATP, which ultimately results in cellular malfunction and an inability to continue maintaining homeostasis. It is possible for cells to display symptoms such as damaged ion balance, decreased ability for protein synthesis, and a buildup of toxic metabolites, all of which have the potential to threaten the integrity and function of the cell.

Furthermore, mitochondria that have been damaged can cause apoptotic cell death by causing the release of pro-apoptotic proteins into the cytoplasm. These molecules include cytochrome c. In addition to its role as an apoptosome component, cytochrome c is an essential component of the electron transport chain. It is responsible for initiating the caspase cascade, which is the process that triggers apoptosis. It is possible for the release of cytochrome c and other apoptotic agents to result in programmed cell death, which in turn contributes to the course of disease and the damage that occurs to tissues.

Disruptions in mitochondrial function have been associated with numerous metabolic diseases. Mitochondrial dysfunction contributes to neuronal death and cognitive decline in neurodegenerative disorders such as Alzheimer's and Parkinson's. Metabolic syndromes, which include diseases like diabetes and obesity, are characterized by mitochondrial dysfunction, which in turn affects glucose metabolism and insulin sensitivity. Because mitochondrial damage has such a broad effect, it is critical to develop therapeutic approaches that aim at reducing oxidative stress and maintaining mitochondrial function. This is because mitochondria are pivotal in cellular health and disease.

Ribosome damage

The translation of genetic information that is encoded in messenger RNA (mRNA) is the process by which ribosomes are essential components of the cellular machinery that is responsible for the synthesis of proteins. Ribosomal RNA (rRNA) and ribosomal proteins are the components that make up these molecular complexes. They collaborate in order to decode the sequence of messenger RNA (mRNA) into a chain of polypeptide acids. The maintenance of cellular homeostasis, the regulation of physiological responses to stress, and the guarantee of appropriate protein creation are all dependent on the ribosomes' ability to work within the cell in an accurate and efficient manner. The dysfunction of ribosomes can have a significant impact on the functioning of cells and the health of the cell as a whole.




Figure 7: Ribosome damage

❖ Damage Mechanisms and Risks

Damage to the ribosomes can be caused by a number of different factors, including as being exposed to chemicals, experiencing oxidative stress, or having a viral infection. Certain poisons, such as ricin, are acknowledged for their ability to precisely target and impair the activity of ribosomes. Ricin, a powerful ribotoxin that is generated from the castor bean plant, binds to rRNA within the ribosome, which results in depurination and disrupts the function of the ribosome to assist protein synthesis. Because of this suppression of ribosomal function, there is a decrease in the creation of proteins, which in turn results in a number of cellular activities being impaired.

Moreover, ribosomes are susceptible to damage when subjected to oxidative stress, which is defined by an excessive amount of reactive oxygen species (ROS). The oxidation of ribosomal proteins and rRNA by reactive oxygen species (ROS) can result in structural alterations that affect the operation of ribosomes. The capacity of the ribosome to accurately translate mRNA into proteins might be rendered ineffective as a consequence of these alterations, which can lead to the synthesis of proteins that are either defective or incomplete. The buildup of such damaged ribosomal components might further worsen the stress that is already present in the cell and disrupt the process of protein synthesis.

Through the targeting and modification of ribosomal components, viral infections can be a contributor to ribosomal damage within the cell. There are certain viruses, such as certain RNA viruses, that create proteins that either interfere with the operation of ribosomes or change ribonucleic acid (rRNA) in order to prefer viral protein synthesis over the generation of proteins by host cells. It is possible that this hijacking of the ribosomal machinery may result in a decrease in the amount of protein that is synthesized by the host cell, which will contribute to the malfunctioning of the cell and may even facilitate viral multiplication.

❖ The repercussions

The repercussions of ribosomal damage are wide and consist of a variety of different aspects. The principal effect is a reduction in the amount of protein that is synthesized, which has an impact on a wide variety of cellular activities. The maintenance of structural integrity, the facilitation of enzyme activities, and the transduction of signals within the cell are all extremely important functions that proteins perform. It is possible for impaired protein synthesis to result in the loss of structural proteins, which in turn reduces the cell's capacity to keep its structure and function together. The ability of the cell to carry out critical biochemical reactions can also be negatively impacted when there is a decline in the production of enzymes, which can also disrupt metabolic pathways.

As a consequence of reduced ribosomal activity, the buildup of proteins that are either damaged or misfolded can put a strain on the quality control systems at the cellular level. These systems, which include chaperone proteins and the ubiquitin-proteasome system, are essential for the management of misfolded proteins and the maintenance of proteostasis in cells. In the event that ribosomal damage results in an excessive amount of faulty proteins, these systems have the potential to become overloaded, which can lead to the accumulation of proteins and cellular toxicity.

The malfunctioning of ribosomes has been linked to a number of different disorders. Alterations in ribosome function can play a role in the development of cancer by contributing to uncontrolled cell growth and proliferation. There is a correlation between ribosomal degradation and poor protein synthesis in neurodegenerative illnesses including Parkinson's disease and Alzheimer's disease. These conditions are related with neuronal loss and cognitive diminishment. The fact that ribosomes play such an important part in the health of cells highlights how essential it is to preserve both their structural integrity and their functional capacity. In the treatment of disorders that are associated with ribosomal dysfunction, therapeutic techniques that target ribosomal damage or its consequences may offer prospective routes leading to viable treatments.

1.1.7 Morphology of Cell Injury – Adaptive Changes

The ability of cells to undergo a variety of adaptive alterations in response to stressors or altered environmental conditions is a characteristic that they possess. Atrophy, hypertrophy, hyperplasia, metaplasia, and dysplasia are the five categories that can be used to classify these adaptive changes, which can be observed morphologically due to their ability to be classified. Every sort of adaptive alteration is a reflection of a particular cellular response that is aimed at preserving homeostasis and ensuring the survival of cells in difficult settings.




Figure 8: Morphology of Cell Injury

❖ Atrophy

Atrophy is a process that is characterized by a reduction in cell size and function. This decline is primarily the result of decreasing cellular workload or adverse environmental conditions. When compared to their normal counterparts, atrophic cells are characterized by a prominent reduction in size and a shrinking of their size. This drop in size is accompanied by a decrease in the volume of the cytoplasm and, frequently, an increase in the density of the organelles that are found in the cytoplasm. The decline in cellular metabolic activity and the loss of cellular components bring for the reduced size of atrophic cells, which is a direct result of the loss of cellular components. An example of atrophy that is frequently seen is in muscle cells that are enduring disuse, such as in situations when the muscle has been immobilized for an extended period of time owing to an injury or disease. Muscles experience a drop in functional demand when they are not consistently engaged in physical exercise, which leads to muscle atrophy by causing the muscles to become less active. This process involves a reduction in the size of muscle fibers as well as a loss of contractile proteins, which ultimately leads to a decrease in the strength and function of the muscles. In a similar manner, atrophy can take place in other tissues or organs when they are subjected to a diminished blood supply, like when they are experiencing ischemia, or when they are experiencing nutrient deficiencies. Ischemic atrophy is a condition that develops when there is a persistent decrease in the amount of blood that flows to tissues. This results in a deficiency of oxygen and nutrients that are essential for the proper functioning and maintenance of cells. A deficit in nutrients, on the other hand, can lead to atrophy because it causes cells to lack the fundamental building blocks that are necessary for them to carry out their usual duties.

A reduction in the number of cellular components, in particular proteins and organelles, is one of the mechanisms that underlies atrophy. Autophagy and enhanced protein degradation are two of the most important processes that contribute to this amount of reduction. The cellular process known as autophagy involves the engulfment of damaged or redundant cellular components by autophagosomes, which are then used by lysosomes to breakdown the components. The recycling of components and the removal of damaged structures are both aspects of this process that contribute to the preservation of cellular homeostasis. In addition to autophagy, the ubiquitin-proteasome pathway is activated, which leads to an increase in the destruction of intracellular proteins. This further contributes to the reduction in the size of the cell. As a result of the combined efforts of these processes, the metabolic demands of the cell are reduced, and the cell is able to adapt to its diminished functional requirements. It is possible

for the effects of atrophy to extend beyond individual cells and affect entire organs or tissues, which can result in a decrease in function and the potential loss of tissue integrity over time. One example is chronic atrophy in the muscles, which can result in considerable weakness and a loss of muscle mass, which in turn can have an effect on mobility and their general physical function. As a similar point of reference, atrophic alterations in organs like the heart or kidneys might affect their capacity to carry out critical functions, which can lead to clinical repercussions and potential health concerns. Atrophy, in general, is a cellular adaptive response to a variety of stresses; but, if it is protracted or severe, it can lead to considerable functional impairments as well as pathological alterations.

❖ Hypertrophy

Hypertrophy is a type of adaptive cellular response that is defined by an increase in cell size. This reaction is often the result of higher functional demands or increased workload. By going through this process, cells are able to improve their functional capability, which enables them to fulfill the increased physiological needs that are placed upon them. Comparatively, hypertrophy is characterized by an increase in the size of individual cells, in contrast to hyperplasia, which is characterized by an increase in the number of cells. This expansion is an essential technique that cells use to adapt to increased demands, which ensures that they can continue to carry out their duties in an effective manner.

When it comes to their morphology, hypertrophic cells are defined by the fact that their cytoplasm is larger and they have a greater collection of organelles. A significant increase in the volume and density of cytoplasmic organelles, in particular mitochondria and endoplasmic reticulum, is one of the most noticeable changes that can be noticed in hypertrophic cells. As a result of the hypertrophied cells' higher energy requirements, mitochondria, which are necessary for the synthesis of energy, proliferate in order to fulfill those requirements. In a similar manner, the endoplasmic reticulum, which plays a role in the synthesis and processing of proteins, grows in size in order to accommodate the increasing production of cellular components. Furthermore, hypertrophic cells frequently have a bigger nucleus, which is indicative of an increased capability for gene expression and protein creation as well as an increased synthesis of nuclear proteins.

It is possible to observe a classic example of hypertrophy in the cells that make up heart muscle. There is a process known as hypertrophy that occurs in cardiac muscle cells as a response to increased pressure overload, which can be observed in conditions such as hypertension or

valvular heart disease. It is imperative that this response be carried out in order to preserve heart function in spite of the high pressures. As a result of the expansion of cardiac muscle cells, the heart is able to create more strong contractions, which enables it to effectively pump blood despite the increasing load. In a similar manner, hypertrophy can also be induced by volume expansion, such as that which is associated with aortic regurgitation. This occurs because the heart learns to adapt to the increased blood volume. The skeletal muscle tissue is another prominent location where hypertrophy can be seen. As a result of the muscle cells adapting to the increased strain, increased physical activity or resistance training causes the muscle fibers to grow in size. A physiological hypertrophy is a type of hypertrophy that occurs as a consequence of an increase in the synthesis of contractile proteins and other structural components within the muscle fibers. This type of hypertrophy is frequently referred to as physiological hypertrophy. An adaptive reaction to the increased mechanical stress that is imposed by physical activity is the growth of muscle cells, which results in an increase in the strength and endurance of the muscle.

❖ **Hyperplasia**

In cellular adaptations, the term "hyperplasia" describes an increase in cell density within a given organ or tissue. An uptick in cell proliferation is responsible for this surge in cell number. Most of the time, this happens in response to a number of factors, such as hormonal signals, chronic pain, or increased functional demands. While hypertrophy is defined by an enlargement of the cell size, hyperplasia is defined by an expansion of the cell population. This adaptive metamorphosis allows tissues and organs to grow and perhaps become more functioning, allowing them to meet greater demands from the body or the environment.

From a morphological standpoint, hyperplasia can be identified by the presence of a greater number of cells inside a particular organ or tissue. This increase in cellularity frequently results in a discernible expansion of the organ or tissue that is currently being impacted. The overall architecture of the tissue typically continues to be rather normal, despite the fact that the number of cells has recently increased. The arrangement and structure of the cells are, for the most part, maintained, although there is a noticeable rise in the number of cells per unit area. In hyperplastic tissues, for instance, the intercellular gaps may become more constricted, and the tissue may appear to be more crowded when viewed through a microscope. An adaptive response to the stimulus is reflected in the enlargement of the organ or tissue, which is caused by the increasing number of cells that contribute to the increased size.

During pregnancy, the glandular epithelium of the breast is shown to exhibit hyperplasia, which is a well-known example of the condition. Within the breast tissue, there is a discernible rise in the proliferation of epithelial cells as a result of hormonal changes, particularly elevated levels of estrogen and progesterone. This phenomenon is characterized by the presence of a noticeable increase. The growth of the glandular tissue that occurs as a result of this hyperplasia is essential for the preparation of the breast for lactation by the body. An adaptive response to the physiological demands of pregnancy and breastfeeding is reflected in the increased number of glandular cells in the breast, which boosts the breast's ability to produce and secrete milk.

One such famous instance of hyperplasia is known as benign prostatic hyperplasia (BPH), which is characterized by the proliferation of prostatic epithelial and stromal cells within the prostate gland. This disorder is frequently seen in males who are getting older and is frequently linked to changes in their hormone levels, particularly elevated levels of dihydrotestosterone (DHT). The proliferation of cells within the prostate leads to an enlargement of the gland, which can produce urinary symptoms such as the need to urinate frequently, difficulties beginning the urination process, and a weak urine stream. The cellular architecture of the prostate is essentially unaffected by benign prostatic hyperplasia (BPH), but the increased cell number causes the organ to become larger, which can cause the urethra to become compressed and can have an impact on urine function.

❖ Metaplasia

Metaplasia is a cellular adaptive response that is characterized by the reversible change of one differentiated cell type into another. This transformation typically occurs as a response to prolonged irritation or environmental stress. The procedure entails the substitution of a cell type that is more sensitive or less robust with a cell type that is more resilient and better equipped to endure the harsh conditions. Furthermore, if the underlying stressor is not addressed, metaplasia might have possible pathological consequences. Metaplasia is a defensive mechanism that aims to maintain tissue function and integrity in the face of chronic insults. However, it can also have potential pathogenic implications.

A change in the cell type inside a tissue can be seen by histological examination, which is the method by which metaplasia is viewed from a morphological perspective. This change often entails the replacement of the original cell type with a new cell type that is better able to deal with the particular stressor that is being experienced. For example, squamous metaplasia is a disease that occurs when the typical ciliated columnar epithelial cells of the respiratory tract

are replaced by squamous epithelial cells as a result of persistent irritation caused by factors such as cigarette smoke. Because they are less resistant to the damaging effects of smoke, ciliated columnar cells, which are normally engaged in the clearance of particulate matter and mucus from the respiratory tract, are less resistant to the effects of smoke. On the other hand, squamous epithelial cells, which are more resistant to irritants, become more numerous in an effort to protect the tissues that lie beneath them from being damaged.

In Barrett's esophagus, a condition characterized by the replacement of normal squamous epithelial cells with columnar epithelial cells, the esophagus is affected by persistent gastroesophageal reflux disease (GERD). This is an additional example of metaplasia that can occur in the gastrointestinal tract. This alteration is an adaptive response that occurs as a result of the esophagus being exposed to acidic gastric contents on a continuous basis. Squamous cells are replaced by columnar cells, which are more resistant to acid, in an effort to preserve the esophagus lining from further damage. Columnar cells are less susceptible to acid. However, Barrett's esophagus is linked to an increased chance of developing esophageal cancer. This demonstrates how metaplasia, which initially protects cells from pathological changes, can predispose cells to more significant pathological changes if the irritant continues to be present.

In the short term, metaplasia can be advantageous since it can provide a more resilient cell type that is better able to resist harsh conditions. However, there is also the possibility that it could have negative consequences. It is possible that the chronic presence of the underlying stressor can result in ongoing cellular alterations and an increased chance of developing dysplasia, which is a condition that is defined by aberrant cell development and organization, and ultimately cancer. In the case of squamous metaplasia in the respiratory epithelium, for example, if smoking is continued, the metaplastic squamous cells may experience dysplastic alterations, which might subsequently lead to the development of malignancy.

❖ **Dysplasia**

The abnormal development or proliferation of cells inside a tissue is referred to as dysplasia. This condition is defined by changes in size, shape, and organization of the cells they consist of. Significant departures from the normal cellular morphology are reflected in this pathological alteration, which is frequently believed to be a forerunner to cancer by medical professionals. Dysplasia is a sign that there has been a breakdown in the regulatory processes

that control cell development and differentiation. This disruption has resulted in abnormal cellular characteristics and a disorderly tissue architecture.

The morphological characteristics of dysplastic cells are characterized by a number of distinct features. Dysplasia is characterized by a number of characteristics, one of which is an aberrant nuclear appearance. Dysplastic cells often display an elevated nuclear-to-cytoplasmic ratio, which indicates that the nucleus occupies a greater proportion of the cell in comparison to the cytoplasm. In dysplastic cells, the nuclear outlines are frequently asymmetrical, and the nucleoli, which are tiny structures within the nucleus that are important in the creation of ribosomes, may become more prominent. The nuclear modifications that have occurred are symptomatic of a disruption in the regulation of the cell cycle as well as an increase in cellular proliferation.

In addition to having aberrant nuclear characteristics, dysplastic cells are structured in a manner that is chaotic within the tissue containing them. When this occurs, the usual architecture of the cell is frequently disrupted, and differences in the size and form of the cell become visible. The loss of normal tissue organization and function is reflected in this disarray which has occurred. There is a possibility that dysplastic tissues would exhibit a lack of the typical stratification and arrangement of cells, which ultimately contributes to the overall structural and functional abnormalities that are found in these tissues.

In epithelial tissues, where it frequently manifests itself as a consequence of persistent irritation or inflammation, dysplasia is the most frequently encountered condition. One example that is particularly noteworthy is cervical dysplasia, which is a condition that can develop as a consequence of maintaining an infection with high-risk human papillomavirus (HPV). HPV infection can cause abnormal cellular changes in the cervix, which, if left untreated, can lead to more severe types of dysplasia and, eventually, cervical cancer. If the condition is not treated, it can proceed to cervical cancer. The progression from dysplasia to carcinoma is characterized by the accumulation of further genetic and epigenetic abnormalities. These modifications are responsible for the transformation from pre-cancerous lesions to fully developed malignant tumors.

In the event that it is not treated, dysplasia has the potential to develop into malignancy, which is the clinical relevance of the condition. Indicative of an increased likelihood of developing cancer, the presence of dysplastic alterations acts as a warning indicator that serves as a warning signal. The detection and treatment of dysplastic lesions at an early stage are absolutely

necessary in order to forestall the development of cancer. This often entails performing routine screenings and monitoring, as well as, in certain instances, therapeutic interventions, with the goal of removing or treating dysplastic regions before they can develop into invasive cancer.

1.1.8 Cell swelling

An important morphological change that takes place when cells experience an imbalance in their internal and external environments, which is typically brought on by an input of water, is referred to as cellular swelling. Cellular edema is another name for this phenomenon. Cellular injury is often the root cause of this illness, which is characterized by a disruption in the processes that manage the cellular ion and fluid balance responsibilities. The failure of the cell's ion pumps, in particular the sodium-potassium ATPase, which normally maintains the appropriate intracellular and extracellular ion concentrations, is the fundamental underlying mechanism that is responsible for this condition.




Figure 9: Cell swelling

Transport of sodium ions out of the cell and potassium ions into the cell are normally carried out by the sodium-potassium ATPase pump. All of this works together to keep the cell's sodium concentration low and its potassium concentration high. By creating an osmotic equilibrium, this gradient regulates the intracellular volume. Sodium ions start to accumulate inside the cell when the pump is weakened, which typically occurs as a result of ischemia, hypoxia, or destructive damage caused by toxic substances. As a consequence of this buildup, an osmotic gradient is created, which forces water to enter the cell in order to counteract the increased osmotic pressure, which ultimately leads to cellular swelling.

The cell's cytoplasm enlarges and the cell membrane's thickness grows as the cell swells. An increase in cell volume and a decrease in the cell's capacity to maintain its structural integrity can be observed under a microscope as this morphological alteration. Enhanced clarity allows for the detection of both of these alterations. In an effort to regulate the increased water content, the cell may enlarge, which could cause the formation of vacuoles inside the cytoplasm. In the long run, the swelling could cause the cell membrane to get compromised as the swelling progresses, which could lead to the membrane bursting and the cell dying.

There are important physiological repercussions associated with cell swelling. It is possible for it to cause compression of the structures that are surrounding the organs in the tissues, which can hinder organ function and contribute to overall tissue edema. When a person has had a brain injury, for instance, the swelling of their cells can contribute to a rise in intracranial pressure, which can result in more damage and a reduction in brain function. Additionally, persistent or severe swelling can cause additional biological processes, such as inflammation or apoptosis, to be triggered in the cell as it seeks to adapt to the damage or repair it. For the purpose of creating treatment techniques to reduce the effects of cell swelling and preserve cellular and tissue function, it is essential to have a solid understanding of the mechanisms and consequences of cell swelling.

1.1.9 Intracellular Accumulation

The term "intracellular accumulation" refers to the accumulation of chemicals within cells that surpass the normal metabolic capacity of the cells itself to handle or remove these compounds. Genetic mutations, metabolic disorders, and environmental exposures are among the many potential causes of substance accumulation, which might manifest as lipids, proteins, carbohydrates, or colors. Each of these elements has the potential to give rise to this phenomenon. The effects and characteristics of intracellular accumulation depend on the drug type and the underlying pathogenic process of the disease.

Lipid accumulation is a typical kind of intracellular accumulation that takes place when there is an imbalance between the synthesis and breakdown of lipids or when there is a defect in the metabolism of lipids. For instance, in situations such as fatty liver disease, an abnormal accumulation of lipids in hepatocytes (liver cells) arises as a result of disruptions in lipid transport or metabolism. These disruptions are sometimes made worse by variables such as excessive use of alcohol or obesity. Consequently, this leads to the enlargement and

malfunctioning of hepatocytes, which, if left untreated, can eventually lead to damage to the liver and cirrhosis.

It is also possible for protein buildup to occur as a consequence of improper protein folding, decreased proteolysis, or increased protein synthesis. A number of disorders, including Alzheimer's disease, are characterized by the accumulation of aberrant proteins, such as amyloid-beta plaques, in neurons where clearance processes are impeded. Because of this accumulation, normal cellular function is disrupted, which contributes to the development of neurodegeneration. In a similar manner, a genetic mutation can cause illnesses such as alpha-1 antitrypsin insufficiency, which results in the accumulation of misfolded alpha-1 antitrypsin protein within liver cells. This accumulation leads to damage to the liver as well as an increased chance of developing emphysema.

When there is a lack of enzymes that are necessary for glycogen metabolism, it can lead to the accumulation of carbohydrates, something that can happen in disorders that involve glycogen storage. This results in an aberrant accumulation of glycogen in tissues, particularly in the liver and muscle, which has an impact on the function of these organs and contributes to metabolic abnormalities.

The accumulation of pigment, which may include the accumulation of melanin, hemosiderin, or lipofuscin, may also be the result of a number of other events. For instance, disorders such as hemochromatosis or persistent bleeding can result in an excessive deposition of hemosiderin, which is a byproduct of iron metabolism. This can lead to damage to tissues and dysfunction in organs. The accumulation of lipofuscin, which is frequently referred to as "age pigment," which is a reflection of oxidative damage and cellular aging, occurs with advancing age and in a variety of degenerative disorders.

The buildup of substances inside of cells can have significant consequences for the functioning of cells and tissues, which can result in pathological situations and contribute to the course of disease. For the purpose of identifying and treating illnesses that are connected with aberrant material building in cells, it is vital to have a solid understanding of the causes and consequences regarding these accumulations.

1.1.10 Calcification

The pathological process known as calcification is characterized by the accumulation of calcium salts in tissues that are not normally present in those tissues. This abnormal

mineralization can take place in a variety of organs and tissues, and it can be roughly divided into two primary categories: dystrophic calcification and metastatic calcification.

A dystrophic calcification is a condition that can occur in tissues that have been damaged or necrotic, and it is not necessarily associated with an abnormal calcium metabolism. Calcium salts are typically deposited in areas of tissue injury, such as atherosclerotic plaques, which are areas where there is ongoing tissue damage and inflammation. This is a typical occurrence. This particular form of calcification is frequently seen in conditions that are characterized by chronic inflammation. In these conditions, tissue that has been damaged or killed acts as a nidus for calcium deposition. A local precipitation of calcium phosphate salts is involved in the process, which can result in the hardening of tissue and a loss of its elasticity. Over the course of time, dystrophic calcification can cause the function of the organs that are affected to become impaired, which can contribute to conditions such as arteriosclerosis or the stiffening of the heart valves.

In contrast, metastatic calcification is linked to systemic abnormalities in calcium metabolism, such as hypercalcemia. This is the case because of the presence of calcium in the body. This illness comes from an overabundance of calcium in the bloodstream, generally related to hyperparathyroidism, vitamin D overdose, or cancer. The high calcium levels lead to the extensive deposition of calcium salts in normal tissues throughout the body, including the lungs, kidneys, and gastrointestinal tract. Metastatic calcification can affect normal tissue function, generating a range of symptoms depending on the organs implicated. For instance, calcium deposits in the kidneys can impair renal function and contribute to kidney stones, whereas deposits in the lungs might impact respiratory function.

Both types of calcifications can have substantial clinical implications, reducing tissue function and leading to disease development. While dystrophic calcification commonly reflects local tissue damage and is typically seen in chronic diseases, metastatic calcification implies a more systemic issue with calcium metabolism. Understanding the underlying causes and consequences of calcification is critical for detecting and managing illnesses linked with aberrant calcium deposition.

1.1.11 Enzyme leakage and Cell Death Acidosis & Alkalosis

❖ Enzyme Leakage and Cell Death

Due to the fact that it reflects a loss of membrane integrity and the subsequent release of internal enzymes into the extracellular environment, enzyme leakage is an essential signal of cellular injury and death. Lactate dehydrogenase (LDH), creatine kinase (CK), and alanine aminotransferase (ALT) are examples of enzymes that are safely stored inside the cytoplasm of the cell as well as in a number of organelles, including mitochondria and the endoplasmic reticulum, when the conditions are normal. These enzymes are absolutely necessary for the proper functioning and metabolism of the cell, and the fact that they are contained within the cell is an indication of the integrity of the membrane and the overall health of the cell. When cells are damaged or die, their plasma membranes become weakened or ruptured. This makes it possible for the enzymes that are found inside the cell to escape into the tissue and bloodstream that surrounds the cell.

Within the context of clinical settings, the leakage of these enzymes functions as an extremely useful diagnostic tool. As an illustration, in the event of a myocardial infarction (also known as a heart attack), the release of cardiac-specific enzymes into the bloodstream, such as CK-MB and troponins, is an essential marker that is utilized for the purpose of diagnosing damage to the heart muscle. An increase in the levels of these enzymes in the blood is an indication that the cells that make up the heart muscle have been injured or have suffered necrosis, which has resulted in the contents of the cells leaking out. Similar to the last example, increased levels of LDH and ALT can be an indication of damage to the liver or other types of tissue injury. The detection and measurement of these enzymes provide clinicians with essential information regarding the level of cellular damage as well as the location of the damage.

A further benefit of enzyme leakage is that it provides information on the pathophysiological processes that are taking place within the body. In many cases, the presence of persistent or substantial leakage of these enzymes is symptomatic of considerable cellular damage or death, which can be indicative of ongoing pathogenic processes. For instance, in diseases such as chronic cardiac ischemia or severe liver illness, continual enzyme leakage might be a reflection of the course of the disease as well as the degree to which cellular necrosis has occurred. Monitoring enzyme levels over a period of time can be helpful in determining the efficacy of therapeutic measures, as well as in tracking the progression of the disease or understanding whether it has been resolved.

The overall conclusion is that enzyme leakage is a significant marker of cellular injury and death, and it offers essential information that may be used for the diagnosis and comprehension of a variety of clinical disorders. The existence of leaky enzymes in the extracellular space or bloodstream, as well as the amounts of those enzymes, can provide information about the extent of cellular damage, the particular tissues or organs that are impacted, and the advancement of diseases that are underlying for the condition. In order to effectively diagnose, treat, and monitor diseases that are associated with cellular injury and death, it is vital to have accurate measurements and interpretations of enzyme leakage.

❖ Acidosis

Acidosis is a condition that is defined by an excess of hydrogen ions (H^+) in the body, which leads to a reduction in blood pH below the normal physiological range of 7.35 to 7.45. Acidosis can also be referred to as a metabolic disorder. In addition to being categorized into two primary categories, metabolic acidosis and respiratory acidosis, this acidic imbalance has the potential to upset the delicate equilibrium that exists between the processes of the body. When there is an accumulation of acidic chemicals or a considerable loss of bicarbonate ions (HCO_3^-), which ordinarily function as a buffer to counteract excess acids, metabolic acidosis occurs. This condition describes the buildup of acidic substances. Common causes include renal failure, which occurs when the kidneys are unable to excrete acids or reabsorb bicarbonate in an adequate manner; diabetic ketoacidosis, which occurs when the body produces an excessive amount of ketone bodies as a result of uncontrolled diabetes, which results in an increase in acidity; and lactic acidosis, which is caused by the accumulation of lactic acid as a result of conditions such as shock or strenuous exercise. As a result of these acidity imbalances, enzyme processes and cellular metabolism might be impaired, which can result in a wide variety of physiological disturbances. These disturbances include decreased energy production and compromised cell function.




Figure 10: Acidosis

On the other hand, respiratory acidosis is primarily brought on by a dysfunction in the capacity of the respiratory system to properly evacuate carbon dioxide (CO₂). When carbon dioxide (CO₂) levels in the blood are elevated, they interact with water to produce carbonic acid (H₂CO₂), which lowers the pH of the blood. This particular form of acidosis is frequently linked to illnesses such as chronic obstructive pulmonary disease (COPD), severe asthma, or other conditions that hinder the function of the lungs and the elimination of carbon monoxide. Consequently, the elevated levels of carbonic acid that are produced lead to an additional reduction in the pH of the blood. Both kinds of acidosis have the potential to result in major clinical manifestations, which may include symptoms such as weariness, confusion, and even coma in extreme circumstances. The body's compensatory mechanisms, which include an increased respiratory rate and renal bicarbonate retention, work to counteract these disturbances. However, when these compensatory responses are overwhelmed or insufficient, clinical management becomes essential in order to restore pH balance and ensure that physiological function is at its optimal level.

❖ Alkalosis

Alkalosis is a condition that is characterized by an increase in the pH level of the blood, which causes a drop in the concentration of hydrogen ions and ultimately results in a pH level that is higher than the usual physiological range of 7.35 to 7.45. There are two primary types of

alkalosis, which are metabolic alkalosis and pulmonary alkalosis. This state of elevated alkalinity can cause disruptions in the regular physiological activities of the body.

When there is a considerable loss of acidic substances from the body or when there is an accumulation of bicarbonate ions (HCO_3^-), metabolic alkalosis can ensue. There are many potential causes that could lead to this imbalance. Hydrochloric acid (HCl) is lost from the stomach as a result of prolonged vomiting, which is one of the most common causes of epigastric distress. The reduction in the overall concentration of hydrogen ions in the blood comes about as a result of the loss of this acidic content, which contributes to an increase in pH. The consumption of an excessive number of alkaline substances, such as antacids or drugs that include bicarbonate, can also be a contributing factor. These chemicals elevate the levels of bicarbonate in the blood and further raise the pH of the blood. It is possible for metabolic alkalosis to affect cellular function by interfering with the activities of enzymes and the processes of biochemistry. Muscle twitching, agitation, and, in more severe cases, arrhythmias or cardiac abnormalities due to disturbed electrolyte balance and reduced cellular function are some of the symptoms that may be associated with this illness.

On the other side, respiratory alkalosis is brought on by hyperventilation, which is a situation in which there is an excessive exhale of carbon dioxide (CO_2). As carbon dioxide (CO_2) reacts with water to produce carbonic acid (H_2CO_2), it plays an important role in maintaining the acid-base balance of the body. When hyperventilation takes place, the levels of carbon dioxide (CO_2) come down, which results in a decrease in carbonic acid and an increase in the pH of the blood. All of these elements, which can lead to an accelerated respiratory rate and thus a loss of carbon dioxide, can be the cause of this syndrome, which can be caused by factors such as worry, fever, or high altitude. Lightheadedness, tingling in the limbs, and muscle cramps are some of the symptoms that can be caused by respiratory alkalosis. This condition can interrupt normal cellular operations and contribute to these symptoms. There are two types of alkalosis, and both of them have the potential to dramatically impact enzyme activity and cellular function, which can result in disruptions to the regular physiological processes. Implementing interventions to restore the acid-base balance and addressing the underlying cause are both necessary components of effective management. This will ensure that the body's systems are able to perform at their highest potential.




Figure 11: Alkalosis

1.1.12 Electrolyte imbalance

In the event that there is an irregularity in the quantities of critical ions in the blood, electrolyte imbalances can emerge. These imbalances have the potential to disturb a diversity of physiological processes. Electrolytes, which include sodium (Na²⁺), potassium (K²⁺), calcium (Ca²⁺), magnesium (Mg²⁺), chloride (Cl²⁺), and bicarbonate (HCO₂⁺), are essential components that play a significant role in the maintenance of fluid balance, the transmission of nerve impulses, and the regulation of muscle activity. It is possible for these ions to cause major health problems and have an effect on a number of organ systems when they are allowed to exceed their usual ranges.

Hyponatremia, which is typically defined by low sodium levels in the blood, is a type of electrolyte imbalance that is observed quite frequently. In order to keep the fluid balance and ensure that cells are functioning properly, sodium is essential. The syndrome of inappropriate antidiuretic hormone secretion (SIADH) is one of the disorders that can lead to hyponatremia. Other conditions that can cause hyponatremia include excessive fluid intake, kidney failure, and hormonal abnormalities. Headaches, nausea, confusion, and, in more severe cases, seizures or coma are some of the symptoms that can become associated with hyponatremia. On the other hand, hypernatremia, often known as high sodium levels, is frequently the consequence of dehydration, kidney disease, or consumed an excessive amount of salt. There is a possibility

that it will result in symptoms such as hunger, bewilderment, twitching of the muscles, and even brain damage in extreme situations.

It is also important to consider the possibility of potassium imbalances, which can present themselves as hypokalemia (low potassium) or hyperkalemia (high potassium). In order to keep the heart rhythm and muscle activity in right order, potassium is absolutely necessary. Symptoms including as weakness, exhaustion, and arrhythmias can be brought on by hypokalemia, which is frequently brought on by prolonged vomiting, diarrhea, or the use of prescription diuretics. The condition known as hyperkalemia, which is typically brought on by renal failure or an excessive consumption of potassium, can result in potentially fatal cardiac arrhythmias and muscle weakness.

Unbalanced calcium levels can have significant repercussions for the neuromuscular function and bone health of someone. Hypocalcemia, which is characterized by low calcium levels, can be the result of a lack of vitamin D, diseases of the parathyroid gland, or renal illness. The symptoms that are most commonly associated with it include cramping in the muscles, tingling, and in more severe cases, tetany or seizures. In most cases, hypercalcemia is brought on by hyperparathyroidism or cancer. This condition can result in a variety of symptoms, including weariness, disorientation, kidney stones, and bone pain.

Magnesium imbalances, such as hypomagnesemia (low magnesium) and hypermagnesemia (high magnesium), have the potential to have an impact on the circulatory and neuromuscular systems. It is possible for hypomagnesemia to be brought on by chronic drunkenness, malabsorption, or the use of particular drugs. This condition can result in symptoms such as tremors, seizures, and cardiac arrhythmias. Lethargy, muscle weakness, and respiratory depression are all symptoms that can be brought on by hypermagnesemia, which is a condition that is less common but is frequently connected with kidney disease or excessive supplementing.

The imbalances of chloride and bicarbonate are similarly significant, despite the fact that they are highlighted less frequently. While bicarbonate, which plays a function in buffering blood pH, is needed for maintaining fluid balance and acid-base balance, chloride is essential for maintaining fluid balance. Imbalances in these electrolytes can be the result of a number of different illnesses, such as metabolic abnormalities or kidney dysfunction.

Electrolyte abnormalities, in general, can result in serious health concerns that affect the cardiovascular system, the neuromuscular system, and the renal system specifically. In order to address these imbalances and prevent significant repercussions, prompt diagnosis and treatment are the most important things that can be done. In order to effectively manage and restore correct physiological function, it is essential to address the underlying cause and continuously monitor electrolyte levels.

1.2 Basic mechanism involved in the process of inflammation and repair:

1.2.1 Introduction

Repair and inflammation are two key mechanisms that the body uses to maintain homeostasis and address cellular and tissue damage. Both of these processes are described below. The immune system's initial reaction to potentially hazardous stimuli, such as viruses, physical injury, or chemical irritants, is inflammation. Inflammation is a defensive mechanism. As a defensive system, it works to eliminate the agent that is causing the problem, remove injured cells, and prepare the body for the process of tissue repair. An intricate interaction between cellular and molecular processes is what makes up the inflammatory response. These processes are aimed to restore the integrity and function of the tissue.




Figure 12: Inflammation

The first step in inflammation is when local immune cells, like macrophages and mast cells, detect harmful stimuli. In reaction to the stimuli, these cells secrete a cascade of signaling chemicals, including chemokines, prostaglandins, and cytokines. Mediators play a crucial role in bringing more immune cells, such as monocytes and neutrophils, to the location of an injury or infection. Changes in blood vessel permeability and the synthesis of adhesion molecules on endothelial cells enable this recruitment. Because of these alterations, immune cells are able to exit the bloodstream and move into the affected tissue. Redness, heat, swelling, and pain are symptoms of an acute inflammatory reaction, which is caused by an increase in blood flow, the buildup of fluid, and the release of inflammatory mediators. Increased blood flow causes these symptoms.

The resolution phase of inflammation involves the elimination of the inflammatory stimulus and the beginning of the healing processes. This phase will occur as the inflammation proceeds. The elimination of inflammatory mediators and the removal of dead cells and pathogens through the process of phagocytosis are the defining characteristics of this developmental phase. The resolution phase gives way to the repair phase, which is characterized by a shift in emphasis toward the regeneration of tissue and the restoration of normal tissue architecture respectively. Repair is accomplished by a number of different mechanisms, such as the proliferation of cells, the remodeling of tissues, and the deposition of components associated with extracellular matrix. When it comes to the synthesis of collagen and other matrix proteins, which are responsible for providing structural support to freshly created tissue, fibroblasts play a very important role.

A condition known as chronic inflammation occurs when the inflammatory response becomes dysregulated and continues for a longer period of time than is typical. This results in continuing tissue damage and healing. A number of illnesses, including autoimmune diseases, persistent infections, and prolonged exposure to irritants, are frequently linked to chronic inflammation. This condition can lead to the development of granulomas or scar tissue, and it has the potential to disrupt the regular functioning of the organs and tissues that are affected.

The process of inflammation and healing is strictly regulated in order to strike a balance between the need for an efficient defense against harmful chemicals and the requirement to restore tissue function and prevent excessive damage. Disruptions in these processes can lead to pathological situations, which highlights the necessity of understanding the mechanisms that

underlie inflammation and repair in order to create efficient therapeutic strategies for the management of inflammatory illnesses and the promotion of tissue healing.

1.2.2 Clinical signs of inflammation

The clinical symptoms of inflammation are manifestations that are the outcome of the complicated response that the body has by itself to an injury or an infection. These indications are a reflection of the underlying physiological and biochemical changes that are taking place at the site of inflammation. They offer vital insights about the presence of the inflammatory process as well as the amount to which it is taking place. Traditional Latin terminology is used to describe the basic clinical manifestations of inflammation. These include redness (rubor), heat (Calor), swelling (tumor), pain (dolor), and loss of function (function lease).

(Rubor) Redness is a visible symptom of inflammation that arises as a result of increased blood flow to the affected area. Redness is also known as coronary artery disease. The phenomena that is referred to as hyperemia is brought about by the expansion of the arterioles and capillaries, which are small blood vessels, in close proximity to the site of an injury or infection. Because of the increased blood flow, immune cells, nutrients, and oxygen are delivered to the tissue that is afflicted, which makes the inflammatory response easier to achieve. As a result of the enlargement of these blood vessels, the skin or mucous membranes seem redder than they normally would. Among the earliest and most obvious indications of inflammation, redness is frequently one of the most prominent.

The presence of heat, also known as Calor, is another characteristic of inflammation. It is closely associated with the appearance of redness. The increased blood flow to the inflamed tissue, which carries more blood with higher temperatures compared to the tissues surrounding it, is the cause of this condition. It is because of the increased metabolic activity and the enhanced perfusion of blood vessels in the affected region that this localized increase in temperature has occurred. One of the factors that can add to the overall discomfort that the patient is experiencing is the sensation of heat, which is especially obvious in places that are superficial.

The buildup of fluid and immune cells in the interstitial space of the damaged tissue is the cause of swelling, also known as edema. Swelling is a clinical manifestation of tumors. This fluid accumulation is a result of increased vascular permeability, which enables plasma proteins and other inflammatory mediators to leak out of the blood vessels and enter the tissues that are

surrounding the blood vessels. Not only does the fluid cause an increase in the volume of the tissue, but it also causes pressure to be exerted on the local structures, which means that it can contribute to pain and functional impairment. Swelling can range from a slight puffiness to a significant expansion of the affected area, depending on the severity of the condition.

Pain, often known as *dolor*, is a significant and frequently uncomfortable symptom of inflammation that can be caused by a number of different sources. Prostaglandins, bradykinin, and histamine are examples of inflammatory mediators that might result in nerve endings in the affected tissue being more sensitive, which in turn leads to an increased experience of pain. Additionally, the pressure that is applied by swelling as well as the release of chemical signals from injured cells can further excite pain receptors. Individuals are prompted to rest and refrain from causing further damage to the damaged area when they experience pain, which functions as a protective mechanism. The intensity of the inflammation can cause the discomfort to range from a dull ache to a severe agony that is excruciating.

Loss of Function (Function Laesa): Loss of function, also known as impaired function, is a consequence of the cumulative effects of inflammation, which include discomfort, swelling, and damage to the tissues. As a result of the physical disturbance brought on by edema, the suppression of normal cellular activities, and the overall influence that inflammation has on the integrity of the tissue, the affected tissue or organ may experience a reduction in its functionality. For instance, inflammation in a joint might result in decreased mobility, and inflammation of the respiratory tract can make it difficult to breathe. The impairment of function is an important clinical aspect that shows the influence that inflammation has on the activities that people do on a daily basis and the quality of life they lead.

Not only are these clinical symptoms essential for diagnosing and determining the extent of inflammation, but they are also essential for determining the most appropriate treatment techniques going forward. The goal of effective therapy of inflammation is to address the underlying cause of the condition, reduce symptoms, and restore normal tissue function. This will ultimately lead to improved patient outcomes and overall well-being.

1.2.3 Different types of Inflammation

Even though it's a necessary biological reaction to harmful stimuli, the inflammatory response can assume several shapes and sizes depending on the stimulus's duration, type, and origin. At its most fundamental level, inflammation can be either acute, chronic, or granulomatous. There

are many different kinds of inflammation, and each one has its own distinct symptoms, causes, and medical consequences.




Figure 13: Types of Inflammation

The body's initial reaction to a disease or damage is known as acute inflammation. It has a short duration and a quick start. This type of inflammation is typically caused by diseases, physical damage, or exposure to pollutants. The symptoms of acute inflammation include redness, heat, swelling, pain, and inflammation. Enhanced blood flow, vascular permeability, and immune cell recruitment to injured tissue are the root causes of these symptoms. These are the hallmarks of acute inflammation. The main biological components of acute inflammation are neutrophils, the first cells that reach the site of injury. Through their efforts, these cells destroy pathogens, clear damaged cells, and kickstart the process of repairing damaged cells. In most cases, acute inflammation is self-limiting, which means that it goes away after the offending factor is eliminated and the tissue starts to heal. The inflammatory response, on the other hand, has the potential to develop into chronic inflammation if it is not appropriately managed.

Inflammation that lasts for a long time—months or even years—is called chronic inflammation. Inflammation that does not go away, despite treatment, causes persistent pain and swelling. Common reasons of this illness include chronic irritation, incomplete healing from an acute inflammatory event, and autoimmune diseases where the immune system attacks healthy tissues. A complex interaction of immune cells, including plasma cells, lymphocytes, and macrophages characterizes chronic inflammation as opposed to acute inflammation, which is marked by neutrophils. Acute inflammation is primarily caused by neutrophils. In addition to their involvement in the ongoing inflammatory process, these cells release mediators such as

cytokines and growth factors that prolong tissue damage and fibrosis. Several diseases and conditions are associated with persistent inflammation; these include inflammatory bowel disease, COPD, rheumatoid arthritis, and inflammatory arthritis. It is associated with several disorders and can lead to serious tissue damage and functional impairment.

Granulomatous inflammation is a specifically described form of chronic inflammation that is characterized by the formation of granulomas. Granulomas are organized groupings of macrophages that have changed into epithelioid cells. Granulomatous inflammation is a specialized form of chronic inflammation. Granulomas are often formed as a reaction to chronic pathogens or foreign bodies that are difficult to eradicate. This pattern of development is seen in illnesses such as tuberculosis, leprosy, and some autoimmune conditions such as sarcoidosis. The granuloma acts as a containment structure, making an effort to separate the pathogen from the surrounding tissue and preventing any additional damage to the tissue. Granulomas, despite the fact that they have the potential to effectively limit the spread of pathogens, can also be a contributor to the development of chronic tissue damage and fibrosis. In many chronic inflammatory disorders, the presence of granulomas is an important diagnostic feature that may be recognized through histological examination of tissue samples. Granulomas can be found in all of these diseases.

Having a thorough understanding of the many forms of inflammation is essential for accurately diagnosing and treating illnesses that are characterized by inflammation. All forms of inflammation call for individualized therapy approaches in order to address the underlying cause, bring the inflammatory response under control, and reduce the amount of tissue damage that occurs. The goal of effective management of inflammation is to restore health and improve quality of life for those who are impacted by it. This can be accomplished through pharmacological therapies, changes in lifestyle, or surgical procedures.

1.2.4 Mechanism of Inflammation – Alteration in vascular permeability and blood flow

A complicated chain of occurrences that ultimately result in alterations in vascular permeability and blood flow are the components that make up the process of inflammation. These changes are essential to the inflammatory response and play a significant part in the recruitment of immune cells, the delivery of nutrients and oxygen, and the removal of toxic substances and debris from the site of damage or infection during the inflammatory response. Having an understanding of these pathways makes it possible to gain insight into the regulation of inflammation and the ways in which it can be modified to enhance therapeutic outcomes.

❖ Modifications to the Vascular Permeability Process:

It is one of the most important characteristics of inflammation that there is an increase in the vascular permeability, which makes it possible for immune cells and plasma proteins to leave the bloodstream and reach the tissue that is being damaged. Several inflammatory mediators, such as histamine, bradykinin, prostaglandins, and leukotrienes, are responsible for mediating this process. The endothelial cells that line the blood arteries are inhibited by these mediators, which causes the cells to contract and results in the formation of intercellular spaces.




Figure 14: Vascular Permeability

The release of histamine, which is predominantly triggered by mast cells and basophils, is responsible for the constriction of endothelial cells, which ultimately results in the development of spaces between cells. As a consequence, this leads to an increase in permeability, which in turn causes fluid and proteins to leak into the interstitial space. This, in turn, contributes to edema, which is swelling at the site of inflammation.

Kallikrein is responsible for the production of the peptide known as bradykinin, which is derived from kininogen. Bradykinin is responsible for the contraction of endothelial cells and the promotion of the release of other inflammatory mediators, both of which contribute to an increase in vascular permeability.

Prostaglandins and leukotrienes are lipid mediators that are formed from arachidonic acid by the activity of cyclooxygenase (COX) and lipoxygenase (LOX) enzymes, respectively.

Prostaglandins are classified as a type of lipid mediator. The effects of histamine and bradykinin are amplified by the presence of prostaglandins and leukotrienes, which contribute to the inflammatory response and further increase the vascular permeability of your blood vessels.

The increased vascular permeability makes it possible for plasma proteins, such as fibrinogen, to be extravasated into the tissue. This protein is then transformed into fibrin within the tissue, which plays a role in the formation of clots. It is through this that the inflammatory process may be contained, and the spread of dangerous chemicals can be prevented.

❖ **Modifications to the Flow of Blood:**

In addition, vasodilation and increased blood flow are the primary mechanisms by which inflammation causes significant changes in blood flow to the afflicted area. These changes are required for the process, which is orchestrated by several mediators, to successfully supply nutrients and immune cells to the site of injury or infection.

Enlargement of blood vessels: When the body detects inflammation, the first reaction is vasodilation. An increase in blood flow to the injured area is the result of this reaction, which increases the diameter of blood vessels to enlarge. Histamine, prostaglandin, and nitric oxide (NO) production is the main mechanism that mediates vasodilation in most situations. Produced by macrophages and endothelial cells, nitric oxide is an effective vasodilator. The smooth muscle cells lining the inside of blood vessels are relaxed, which allows more blood to flow through the body.

An increase in blood flow to the area of inflammation is the cause of the redness (rubor) and heat (Calor) that are visible during inflammation. Because of this, the inflammation has occurred. The wounded tissue receives more oxygen, nutrients, and immune cells due to the enhanced perfusion, which aids in the inflammatory response and tissue repair.

Stasis and Margination: Blood flow in the affected vessels slows down over time as inflammation gets worse; this phenomenon is called stasis. The endothelial cells get attached to leukocytes—especially neutrophils—when blood flow slows down, allowing them to marginate, or relocate to the artery wall. This process is mediated in part by adhesion molecules including integrins and selectins. Leukocytes can cling to tissues and migrate around inside them with the help of these substances.

1.2.5 Migration of WBC's

In order for the body to effectively defend itself against injury and infection, one of the most important processes is the migration of white blood cells (WBCs), which are also referred to as leukocytes, to areas of inflammation. A series of well-coordinated stages are required for this process, which is known as leukocyte extravasation. These steps make it possible for white blood cells to travel from the bloodstream into the tissues that are damaged. The immune response is comprised of several processes, each of which plays an important role in the process. These steps include margination, rolling, adhesion, diapedesis, and chemotaxis.

1. The concept of rolling and margining:

Stasis, also known as a slowing down of blood flow, is a consequence of changes in blood flow dynamics that occur in the early stages of inflammation. These changes include vasodilation and increased vascular permeability. Leukocytes, which generally move along the central axis of the blood artery, are able to move closer to the endothelium lining as a result of this process, which is referred to as margination.

As soon as leukocytes get close to the vessel wall, they go through a process known as "rolling," which is made possible by selectin molecules that are found on the surface of endothelial cells. These selectins form a momentary attachment to their carbohydrate ligands on the leukocytes, which results in the leukocytes rolling down the surface of the endothelium. The leukocytes are able to slow down and search the endothelium cells for signals that indicate the location of the inflammation when they roll.

2. The adhesion of:

Following the rolling process, leukocytes go through a process of adhesion to the endothelium that is mediated by integrins. Integrins are cell surface receptors that are found on leukocytes. These receptors and their related ligands are found on endothelial cells. One example of an integrin is ICAM-1, which stands for intercellular adhesion molecule-1. In the beginning, this binding is not very strong, but it gets more powerful when it is activated by chemokines that are released at the site of inflammation.

Because of the interaction between integrins and their ligands, leukocytes are able to firmly cling to the surface of the endothelium, which allows them to stand up to the shear stresses that

are caused by blood flow. Furthermore, the following transmigration of leukocytes across the endothelium barrier is dependent upon the successful completion of this step.

3. Transmigration, also known as diapedesis

Leukocytes go through a process called diapedesis, which is also referred to as transmigration, once they have firmly stuck to the endothelium. This process involves the passage of leukocytes between or through endothelial cells, which enables the leukocytes to leave the bloodstream and enter the tissue that is surrounding them.

The process of diapedesis is made easier by the rearrangement of the cytoskeleton that occurs within the leukocytes as well as the endothelial cells. During this process, endothelial cells temporarily relax their tight connections, which results in the formation of gaps that allow leukocytes to flow through. There is also the possibility that leukocytes will secrete enzymes such as matrix metalloproteinases (MMPs) in order to destroy the basement membrane, which will further facilitate their entry into the tissue.

4. Chemotaxis, number

Chemotaxis is a mechanism that uses chemical gradients of attractant molecules known as chemokines to direct leukocytes to the site of damage or infection after they have transmigrated. Chemotaxis is a process that occurs after transmigration. There are a number of cells that are responsible for the release of chemokines at the site of inflammation. These cells include macrophages, endothelial cells, and destroyed tissue cells.

Until they reach the origin of the signal, leukocytes will continue to travel in the direction of rising chemokine concentration, following the gradient. Because of this tailored migration, leukocytes are able to accumulate precisely where they are required to carry out their immunological tasks.

5. Phagocytosis and activation of the cell:

Leukocytes, particularly neutrophils and macrophages, get activated and begin the process of phagocytosis as soon as they arrive at the site of inflammation. Phagocytosis is the process by which these cells consume and digest waste, dead cells, and microorganisms that are harmful to the body. In addition, activated leukocytes secrete a number of enzymes, reactive oxygen species (ROS), and cytokines, all of which contribute to the elimination of potential dangers and the facilitation of tissue healing.

To summarize, the migration of white blood cells (WBCs) to sites of inflammation is a process that is precisely calibrated and involves numerous processes that provide a successful immune response for the body. Each aspect of the immune system's process, beginning with the earliest steps of margination and rolling and continuing with the latter stages of chemotaxis and activation, is essential to the immune system's ability to effectively defend the body against diseases and injuries. When these processes are understood, it is possible to gain a better understanding of the mechanisms that are responsible for inflammatory disorders. This understanding can also assist in the creation of treatment techniques that can influence their migration and inflammation.

1.2.6 Mediators of inflammation

There is a broad set of molecules known as mediators of inflammation. These molecules are responsible for orchestrating the intricate sequence of events that occur during the inflammatory response. In addition to cytokines, histamines, prostaglandins, leukotrienes, and complement proteins, these mediators are also produced by immune cells, endothelial cells, and injured tissues. These mediators are responsible for regulating the immune system. To ensure that the body is able to efficiently respond to an injury or infection while minimizing potential harm to healthy tissues that are surrounding the affected area, their primary function is to begin, amplify, and end the inflammatory process.




Figure 15: Mediators of inflammation

Cytokines are signaling proteins secreted by immune cells such as lymphocytes, mast cells, and macrophages. One of the most important parts of controlling inflammation is cytokines. There are cytokines that significantly contribute to inflammation, such as interleukin-1 (IL-1), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF- α). These cytokines help get other immune cells activated and sent straight to the infection or damage site. Additionally, they facilitate leukocyte extravasation by elevating the expression of adhesion molecules on endothelial cells. On top of that, they encourage the liver to produce acute-phase proteins.

There are granules of mast cells, basophils, and platelets that contain histamines. Histamines are vasoactive amines. When they are released, they cause the blood vessels to dilate, which is known as vasodilation, and they also increase the permeability of the blood vessels, which results in the standard symptoms of inflammation, which include redness and swelling. Through its action on nerve endings, histamine is also responsible for the itching and pain that are connected to inflammation.

Two types of lipid-derived mediators are known as prostaglandins and leukotrienes. Prostaglandins and leukotrienes are produced from arachidonic acid, which is a component of phospholipids found in cell membranes. As a result of their ability to enhance vasodilation, increase vascular permeability, and sensitize nerve terminals to pain, prostaglandins, which are generated by the enzyme cyclooxygenase (COX), play a crucial part in sustaining inflammation. It is also through their action on the hypothalamus that they mediate fever. Leukotrienes, generated by the enzyme lipoxygenase, are powerful chemotactic agents that attract neutrophils and other leukocytes to the site of inflammation, contributing to the buildup of immune cells in the damaged tissue.

Complement System: The complement system is a network of plasma proteins that enhance the body's immune response by facilitating the elimination of pathogens by phagocytic cells and antibodies. Activation of the complement cascade results in the production of complement fragments such as C3a and C5a. Anaphylatoxins, made by these complement fragments, increase blood vessel permeability and attract immune cells to the site of an injury or infection. In addition, opsonization of infections is facilitated by the complement system, which facilitates the recognition and consumption of these pathogens by phagocytes.

An integral part of the inflammatory response's mechanism of action is the peptide bradykinin, which causes vasodilation, increases vascular permeability, and induces pain. In the later phases of inflammation, it becomes a highly important component, and its production is

regulated by the kinin-kallikrein system. Bradykinin intensifies the inflammatory response by triggering the secretion of additional mediators, including prostaglandins and nitric oxide.

Nitric oxide (NO) is a short-lived free radical that is produced by a variety of cells, including certain neurons, macrophages, and endothelial cells. It regulates leukocyte adhesion and migration and vasodilates to increase blood flow to injured areas, among its several functions in inflammatory processes. In addition to its antibacterial properties, NO helps eliminate infections by destroying microbes right where they started.

When these mediators work together, the inflammatory response is quick and effective. These compounds help activate several parts of the immune system, which in turn helps recruit immune cells, widen blood vessels, and improve vascular permeability. Nevertheless, it is critical to keep things in perspective and adhere to the rules of these mediators. A chronic inflammatory response, whether excessive or prolonged, can cause tissue damage and is a component of diseases like autoimmune disorders, arthritis, and atherosclerosis. Consequently, in order to develop medications that can manage inflammation and treat diseases linked to it, a thorough comprehension of the functions and regulation of inflammatory mediators is essential.

1.2.7 Basic principles of wound healing in the skin

In the skin, wound healing is a multifaceted and ever-changing process that involves the restoration of the integrity of damaged tissue through a series of events that are coordinated with one another. The process of tissue repair requires the participation of a number of different cell types, signaling molecules, and components of the extracellular matrix, all of which collaborate with one another. The fundamentals of wound healing can be broken down into four phases that overlap with one another: hemostasis, inflammation, proliferation, and remodeling.

Hemostasis is the start of the initial phase of wound healing, which begins soon after an injury and has the primary objective of preventing further bleeding. Blood vessels in the affected area constrict, resulting in a reduction in the amount of blood that flows through them. At the site of the damage, platelets get activated and begin to aggregate, which results in the formation of a temporary clot through the cascade of coagulation factors. This clot not only stops any additional blood loss, but it also acts as a scaffold for the recruitment of immune cells and other components that are necessary for the healing process.




Figure 16: healing in the skin

Inflammation: After the hemostatic phase has been completed, the inflammatory phase begins, and it normally continues for a number of days. In this phase, immune cells such as neutrophils, macrophages, and lymphocytes travel to the wound site in response to signals emitted from the clot and damaged tissue. This phase is characterized by the proliferation of immune cells. Neutrophils are the first cells to arrive, and through the process of phagocytosis, they consume and eliminate waste and bacteria throughout the body. Macrophages are the next cells to arrive, and they perform a dual function by removing debris and secreting growth factors that encourage the subsequent phase of the healing process. The process of inflammation is essential for the elimination of pathogens and the preparation of the wound bed for the development of new tissue; nevertheless, it must be strictly controlled in order to prevent an excessive amount of tissue damage.

The production of new tissue is seen during the proliferation phase, which begins a few days after an injury and continues for several weeks. This phase is characterized by the formation of new tissue. Within this phase, the mechanisms of re-epithelialization, angiogenesis, and the

creation of granulation tissue are considered to be highly significant. As part of the process of restoring the epithelial layer, keratinocytes, which are the main cells in the epidermis, move across the wound bed. The freshly produced tissue receives structural support from fibroblasts, which simultaneously proliferate and produce collagen and other proteins that are found in the extracellular matrix through the process of synthesis. The process of angiogenesis, which involves the development of new blood vessels from existing ones, guarantees that the tissue that is being healed receives an adequate supply of oxygen and nutrients. During this phase, granulation tissue is created, and it has a high concentration of new blood vessels, fibroblasts, and immune cells. These cells work together to fill the wound and replace the clot.

The next and last phase of wound healing is called remodeling, and it can span anywhere from a few months to many years, depending on the severity of the injury. During this phase, the granulation tissue is gradually replaced by an extracellular matrix that is more organized and richer in collagen. This matrix provides the healed tissue with strength and durability. Realignment and cross-linking of collagen fibers are two processes that are utilized in order to enhance the tensile strength of scar tissue. The repaired skin may not have the same strength or function as the tissue that was not harmed, and there is typically some degree of scarring present. However, the wound region does restore a significant portion of its original structure through the healing process.

Throughout the entirety of the process, a number of growth factors, cytokines, and enzymes are responsible for regulating the activity and interaction of diverse cell types. The rate at which wounds heal and the degree to which they are successful can be affected by a variety of factors, including diet, blood flow, infection, and the individual's overall health. For the purpose of devising strategies to improve clinical outcomes, promote recovery, and limit complications in patients who have acute or chronic wounds, it is vital to have a fundamental understanding of the principles underlying wound healing.

1.2.8 Pathophysiology of Atherosclerosis

Atherosclerosis is a complicated and persistent inflammatory disease that affects the artery walls. It is defined by the buildup of lipids, inflammatory cells, and fibrous materials, which ultimately results in the creation of atherosclerotic plaques of the arterial walls. This syndrome is a significant contributor to the development of cardiovascular disorders, such as coronary artery disease, stroke, and peripheral artery disease. Plaque formation and possible problems such as thrombosis or artery obstruction are the culmination of a number of processes that are

involved in the pathophysiology of atherosclerosis. These phases begin with endothelial damage and culminate for plaque formation.

The pathogenesis of atherosclerosis begins with damage to the endothelial cells that line the walls of the arteries. The malfunction of endothelial cells is what causes this harm. Hyperlipidemia (excessive levels of LDL cholesterol and other lipids), smoking, diabetes, and high blood pressure are among the many risk factors that can cause this injury. The two hallmarks of endothelial dysfunction are an increase in the expression of adhesion molecules and a decrease in the generation of nitric oxide, a vasodilator. This change in endothelial function enables adherence of circulating monocytes and lymphocytes to the endothelium's surface.

After endothelial injury, lipids, particularly LDL cholesterol, are able to permeate the endothelium layer and deposit in the subendothelial space. This process is known as lipid accumulation. An essential stage in the progression of atherosclerosis is the oxidation of these LDL particles, which is a process that takes place. In addition to being extremely pro-inflammatory, oxidized low-density lipoprotein (ox-LDL) also encourages the recruitment of monocytes from the bloodstream into the artery wall. Upon entering the body, monocytes undergo a process of differentiation into macrophages, which then consume ox-LDL particles and change into foam cells. One of the earliest obvious lesions of atherosclerosis is the formation of fatty streaks, which are caused by the aggregation of foam cells.

A chronic inflammatory response within the arterial wall is maintained by the continuous buildup of foam cells and the secretion of inflammatory cytokines. Another factor that contributes to this reaction is plaque buildup. There are several immune cells, including T-lymphocytes, that help create this inflammatory environment. In reaction to the inflammation, smooth muscle cells from the innermost layer of the artery (the intima) migrate from the outermost layer (the tunica media) and multiply. The fibrous cap that covers the lipid-rich core of the plaque is mostly the result of the creation of extracellular matrix components like elastin and collagen by these smooth muscle cells. This fibrous covering stabilizes the plaque, but it might cause additional, more serious problems if it becomes weak and ruptures easily.

Plaque Progression and Complications: As the atherosclerotic plaque grows, it has the potential to enlarge and protrude into the artery lumen, which can result in a decrease in blood flow. The plaque has the potential to become calcified over time, which will further stiffen the artery and contribute to the development of arterial hypertension. A significant complication of

atherosclerosis is the rupture of the fibrous cap, which exposes the thrombogenic core that lies under the fibrous cap to the blood that is present in circulation. It is possible for this rupture to cause the creation of a blood clot, also known as a thrombus, at the location. This clot has the potential to partially or totally obstruct the artery, which can result in ischemic events such as myocardial infarction (also known as a heart attack) or another type of stroke.

Plaques can become highly calcified and fibrotic in advanced stages, which can lead to persistent occlusion of the vessel and restricted blood supply to tissues. Aneurysm formation can also occur in advanced stages of the disease. Aneurysms are abnormal dilations of the vessel that can be caused by the weakening of the arterial wall that occurs as a result of the atherosclerotic process. This can occur in certain instances. There is a possibility that aneurysms will burst, which could lead to a bleeding that is potentially fatal.

Atherosclerosis is a progressive disease with multiple potential causes, including heredity, the environment, and one's way of life. Its complicated development requires lipid metabolism, endothelial function, immune response, and hemodynamic variables. Atherosclerosis is the top cause of death and disability globally, therefore understanding its pathophysiology is crucial for developing treatments and prevention measures.

References

1. Adapa, S., Aeddula, N. R., Konala, V. M., Chenna, A., Naramala, S., Madhira, B. R., ... & Bose, S. (2020). COVID-19 and renal failure: challenges in the delivery of renal replacement therapy. *Journal of clinical medicine research*, 12(5), 276.
2. Adiamah, A., Skorepa, P., Weimann, A., & Lobo, D. N. (2019). The impact of preoperative immune modulating nutrition on outcomes in patients undergoing surgery for gastrointestinal cancer: a systematic review and meta-analysis. *Annals of Surgery*, 270(2), 247-256.
3. Ahmed, M., & Ahmed, S. (2019). Functional, diagnostic and therapeutic aspects of gastrointestinal hormones. *Gastroenterology research*, 12(5), 233.
4. Alam, A., Thelin, E. P., Tajsic, T., Khan, D. Z., Khellaf, A., Patani, R., & Helmy, A. (2020). Cellular infiltration in traumatic brain injury. *Journal of neuroinflammation*, 17, 1-17.
5. Alizadeh, A., Dyck, S. M., & Karimi-Abdolrezaee, S. (2019). Traumatic spinal cord injury: an overview of pathophysiology, models and acute injury mechanisms. *Frontiers in neurology*, 10, 282.
6. Ansari, J., & Gavins, F. N. (2019). Ischemia-reperfusion injury in sickle cell disease: from basics to therapeutics. *The American Journal of Pathology*, 189(4), 706-718.
7. Arnett, D. K., Blumenthal, R. S., Albert, M. A., Buroker, A. B., Goldberger, Z. D., Hahn, E. J., ... & Ziaeian, B. (2019). 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Journal of the American College of Cardiology*, 74(10), 1376-1414.
8. Arnett, D. K., Blumenthal, R. S., Albert, M. A., Buroker, A. B., Goldberger, Z. D., Hahn, E. J., ... & Ziaeian, B. (2019). 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Circulation*, 140(11), e596-e646.
9. Ashley, C., & Dunleavy, A. (2018). *The renal drug handbook: the ultimate prescribing guide for renal practitioners*. CRC press.
10. Authors/Task Force Members:, McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., ... & Waltenberger, J. (2022). 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology

- (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. *European journal of heart failure*, 24(1), 4-131.
11. Bagwe-Parab, S., Yadav, P., Kaur, G., Tuli, H. S., & Buttar, H. S. (2020). Therapeutic applications of human and bovine colostrum in the treatment of gastrointestinal diseases and distinctive cancer types: The current evidence. *Frontiers in Pharmacology*, 11, 01100.
 12. Barros, L. L., Farias, A. Q., & Rezaie, A. (2019). Gastrointestinal motility and absorptive disorders in patients with inflammatory bowel diseases: Prevalence, diagnosis and treatment. *World journal of gastroenterology*, 25(31), 4414.
 13. Bektas, A., Schurman, S. H., Sen, R., & Ferrucci, L. (2018). Aging, inflammation and the environment. *Experimental gerontology*, 105, 10-18.
 14. Benfaremo, D., Manfredi, L., Luchetti, M. M., & Gabrielli, A. (2018). Musculoskeletal and rheumatic diseases induced by immune checkpoint inhibitors: a review of the literature. *Current drug safety*, 13(3), 150-164.
 15. Bennett, C. F., Latorre-Muro, P., & Puigserver, P. (2022). Mechanisms of mitochondrial respiratory adaptation. *Nature Reviews Molecular Cell Biology*, 23(12), 817-835.
 16. Berk, M., Köhler-Forsberg, O., Turner, M., Penninx, B. W., Wrobel, A., Firth, J., ... & Marx, W. (2023). Comorbidity between major depressive disorder and physical diseases: a comprehensive review of epidemiology, mechanisms and management. *World Psychiatry*, 22(3), 366-387.
 17. Biver, E., Berenbaum, F., Valdes, A. M., de Carvalho, I. A., Bindels, L. B., Brandi, M. L., ... & Rizzoli, R. (2019). Gut microbiota and osteoarthritis management: An expert consensus of the European society for clinical and economic aspects of osteoporosis, osteoarthritis and musculoskeletal diseases (ESCEO). *Ageing research reviews*, 55, 100946.
 18. Black, L. M., Lever, J. M., & Agarwal, A. (2019). Renal inflammation and fibrosis: a double-edged sword. *Journal of Histochemistry & Cytochemistry*, 67(9), 663-681.
 19. Bojar, R. M. (2020). *Manual of perioperative care in adult cardiac surgery*. John Wiley & Sons.
 20. Bonanni, R., Cariati, I., Tancredi, V., Iundusi, R., Gasbarra, E., & Tarantino, U. (2022). Chronic pain in musculoskeletal diseases: Do you know your enemy?. *Journal of clinical medicine*, 11(9), 2609.
 21. Boothby, I. C., Cohen, J. N., & Rosenblum, M. D. (2020). Regulatory T cells in skin injury: At the crossroads of tolerance and tissue repair. *Science immunology*, 5(47), eaaz9631.

22. Calabrese, L. H., Calabrese, C., & Cappelli, L. C. (2018). Rheumatic immune-related adverse events from cancer immunotherapy. *Nature Reviews Rheumatology*, 14(10), 569-579.
23. Carter, P., Lagan, J., Fortune, C., Bhatt, D. L., Vestbo, J., Niven, R., ... & Miller, C. A. (2019). Association of cardiovascular disease with respiratory disease. *Journal of the American College of Cardiology*, 73(17), 2166-2177.
24. Castiglione, V., Aimo, A., Vergaro, G., Saccaro, L., Passino, C., & Emdin, M. (2022). Biomarkers for the diagnosis and management of heart failure. *Heart failure reviews*, 1-19.
25. Chavakis, T., Mitroulis, I., & Hajishengallis, G. (2019). Hematopoietic progenitor cells as integrative hubs for adaptation to and fine-tuning of inflammation. *Nature immunology*, 20(7), 802-811.
26. Chen, L., Deng, H., Cui, H., Fang, J., Zuo, Z., Deng, J., ... & Zhao, L. (2018). Inflammatory responses and inflammation-associated diseases in organs. *Oncotarget*, 9(6), 7204.
27. Chen, Y., Huang, T., Yu, Z., Yu, Q., Wang, Y., Hu, J. A., ... & Yang, G. (2022). The functions and roles of sestrins in regulating human diseases. *Cellular & Molecular Biology Letters*, 27, 1-24.
28. Cheville, A., Smith, S., Barksdale, T., & Asher, A. (2021). Cancer rehabilitation. *Braddom's Physical Medicine and Rehabilitation*, 568-593.
29. Craig, E., & Cappelli, L. C. (2018). Gastrointestinal and hepatic disease in rheumatoid arthritis. *Rheumatic Disease Clinics*, 44(1), 89-111.
30. Cristina, N. M., & Lucia, D. A. (2021). Nutrition and healthy aging: Prevention and treatment of gastrointestinal diseases. *Nutrients*, 13(12), 4337.
31. Cruz, C. S. D., & Kang, M. J. (2018). Mitochondrial dysfunction and damage associated molecular patterns (DAMPs) in chronic inflammatory diseases. *Mitochondrion*, 41, 37-44.
32. Dainton, M. (2024). Acute kidney injury. *Renal nursing: care and management of people with kidney disease*, 115-131.
33. Dalili, D., Isaac, A., Bazzocchi, A., Åström, G., Bergh, J., Lalam, R., ... & Mansour, R. (2020, December). Interventional techniques for bone and musculoskeletal soft tissue tumors: current practices and future directions-part I. ablation. In *Seminars in Musculoskeletal Radiology* (Vol. 24, No. 06, pp. 692-709). Thieme Medical Publishers, Inc..
34. Damluji, A. A., Forman, D. E., Van Diepen, S., Alexander, K. P., Page, R. L., Hummel, S. L., ... & American Heart Association Council on Clinical Cardiology and Council on Cardiovascular and Stroke Nursing. (2020). Older adults in the cardiac intensive care unit:

- factoring geriatric syndromes in the management, prognosis, and process of care: a scientific statement from the American Heart Association. *Circulation*, 141(2), e6-e32.
35. De Ligt, K. M., Heins, M., Verloop, J., Smorenburg, C. H., Korevaar, J. C., & Siesling, S. (2019). Patient-reported health problems and healthcare use after treatment for early-stage breast cancer. *The Breast*, 46, 4-11.
 36. Domínguez-Andrés, J., Dos Santos, J. C., Bekkering, S., Mulder, W. J., van der Meer, J. W., Riksen, N. P., ... & Netea, M. G. (2023). Trained immunity: adaptation within innate immune mechanisms. *Physiological reviews*, 103(1), 313-346.
 37. Drewes, A. M., Olesen, A. E., Farmer, A. D., Szigethy, E., Rebours, V., & Olesen, S. S. (2020). Gastrointestinal pain. *Nature reviews Disease primers*, 6(1), 1.
 38. Dumitru, C., Kabat, A. M., & Maloy, K. J. (2018). Metabolic adaptations of CD4+ T cells in inflammatory disease. *Frontiers in Immunology*, 9, 540.
 39. Ekinci, C., Karabork, M., Siriopol, D., Dincer, N., Covic, A., & Kanbay, M. (2018). Effects of volume overload and current techniques for the assessment of fluid status in patients with renal disease. *Blood Purification*, 46(1), 34-47.
 40. Elad, S., Zadik, Y., Caton, J. G., & Epstein, J. B. (2019). Oral mucosal changes associated with primary diseases in other body systems. *Periodontology 2000*, 80(1), 28-48.
 41. ElHawary, H., Baradaran, A., Abi-Rafeh, J., Vorstenbosch, J., Xu, L., & Efanov, J. I. (2021, August). Bone healing and inflammation: principles of fracture and repair. In *Seminars in plastic surgery* (Vol. 35, No. 03, pp. 198-203). Thieme Medical Publishers, Inc..
 42. Elkon, K. B. (2018). Cell death, nucleic acids, and immunity: inflammation beyond the grave. *Arthritis & Rheumatology*, 70(6), 805-816.
 43. El-Tallawy, S. N., Nalamasu, R., Salem, G. I., LeQuang, J. A. K., Pergolizzi, J. V., & Christo, P. J. (2021). Management of musculoskeletal pain: an update with emphasis on chronic musculoskeletal pain. *Pain and therapy*, 10, 181-209.
 44. Enck, P., & Mazurak, N. (2018). The “Biology-First” Hypothesis: Functional disorders may begin and end with biology—A scoping review. *Neurogastroenterology & Motility*, 30(10), e13394.
 45. ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2—care pathways, treatment, and follow-up." *Cardiovascular Research* 118, no. 7 (2022): 1618-1666.
 46. Felgueiras, H. P., Antunes, J. C., Martins, M. C. L., & Barbosa, M. A. (2018). Fundamentals of protein and cell interactions in biomaterials. In *Peptides and Proteins as Biomaterials for Tissue Regeneration and Repair* (pp. 1-27). Woodhead Publishing.

47. Fisher, L., Fisher, A., & Smith, P. N. (2020). Helicobacter pylori related diseases and osteoporotic fractures (Narrative Review). *Journal of clinical medicine*, 9(10), 3253.
48. Gadiparthi, C., Hans, A., Potts, K., & Ismail, M. K. (2018). Gastrointestinal and hepatic disease in the inflammatory myopathies. *Rheumatic Disease Clinics*, 44(1), 113-129.
49. Gerstein, H. C., Sattar, N., Rosenstock, J., Ramasundarahettige, C., Pratley, R., Lopes, R. D., ... & Branch, K. (2021). Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes. *New England journal of medicine*, 385(10), 896-907.
50. Gragnano, A., Negrini, A., Miglioretti, M., & Corbière, M. (2018). Common psychosocial factors predicting return to work after common mental disorders, cardiovascular diseases, and cancers: a review of reviews supporting a cross-disease approach. *Journal of occupational rehabilitation*, 28, 215-231.
51. Gusev, E., & Zhuravleva, Y. (2022). Inflammation: A new look at an old problem. *International Journal of Molecular Sciences*, 23(9), 4596.
52. Haanen, J., Ernstoff, M. S., Wang, Y., Menzies, A. M., Puzanov, I., Grivas, P., ... & Obeid, M. (2020). Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention strategy. *Annals of oncology*, 31(6), 724-744.
53. Healy, L. M., Yaqubi, M., Ludwin, S., & Antel, J. P. (2020). Species differences in immune-mediated CNS tissue injury and repair: A (neuro) inflammatory topic. *Glia*, 68(4), 811-829.
54. Heerspink, H. J., Sjöström, C. D., Jongs, N., Chertow, G. M., Kosiborod, M., Hou, F. F., ... & Wheeler, D. C. (2021). Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial. *European heart journal*, 42(13), 1216-1227.
55. Hines, R. L., & Jones, S. B. (Eds.). (2021). *Stoelting's Anesthesia and Co-Existing Disease E-Book: Stoelting's Anesthesia and Co-Existing Disease E-Book*. Elsevier Health Sciences.
56. Hollenberg, S. M., Warner Stevenson, L., Ahmad, T., Amin, V. J., Bozkurt, B., Butler, J., ... & Storrow, A. B. (2019). 2019 ACC expert consensus decision pathway on risk assessment, management, and clinical trajectory of patients hospitalized with heart failure: a report of the American College of Cardiology Solution Set Oversight Committee. *Journal of the American College of Cardiology*, 74(15), 1966-2011.
57. Hong, Y., Wu, C., & Wu, B. (2020). Effects of resistance exercise on symptoms, physical function, and quality of life in gastrointestinal cancer patients undergoing chemotherapy. *Integrative Cancer Therapies*, 19, 1534735420954912.

58. Huang, K., Cai, H. L., Bao, J. P., & Wu, L. D. (2020). Dehydroepiandrosterone and age-related musculoskeletal diseases: Connections and therapeutic implications. *Ageing Research Reviews*, 62, 101132.
59. Humphrey, J. D., & Schwartz, M. A. (2021). Vascular mechanobiology: homeostasis, adaptation, and disease. *Annual review of biomedical engineering*, 23(1), 1-27.
60. Inglis, J. E., Lin, P. J., Kerns, S. L., Kleckner, I. R., Kleckner, A. S., Castillo, D. A., ... & Peppone, L. J. (2019). Nutritional interventions for treating cancer-related fatigue: a qualitative review. *Nutrition and cancer*, 71(1), 21-40.
61. Irani, S. (2020). New insights into oral cancer—Risk factors and prevention: A review of literature. *International Journal of Preventive Medicine*, 11.
62. James, M. T., Levey, A. S., Tonelli, M., Tan, Z., Barry, R., Pannu, N., ... & Hemmelgarn, B. R. (2019). Incidence and prognosis of acute kidney diseases and disorders using an integrated approach to laboratory measurements in a universal health care system. *JAMA Network Open*, 2(4), e191795-e191795.
63. Jansen, F. M., Vavricka, S. R., den Broeder, A. A., de Jong, E. M., Hoentjen, F., & van Dop, W. A. (2020). Clinical management of the most common extra-intestinal manifestations in patients with inflammatory bowel disease focused on the joints, skin and eyes. *United European gastroenterology journal*, 8(9), 1031-1044.
64. Jentzer, J. C., Bihorac, A., Brusca, S. B., Del Rio-Pertuz, G., Kashani, K., Kazory, A., ... & Critical Care Cardiology Working Group of the Heart Failure and Transplant Section Leadership Council. (2020). Contemporary management of severe acute kidney injury and refractory cardiorenal syndrome: JACC council perspectives. *Journal of the American College of Cardiology*, 76(9), 1084-1101.
65. Kalantar-Zadeh, K., Jafar, T. H., Nitsch, D., Neuen, B. L., & Perkovic, V. (2021). Chronic kidney disease. *The lancet*, 398(10302), 786-802.
66. Kalantar-Zadeh, K., Lockwood, M. B., Rhee, C. M., Tantisattamo, E., Andreoli, S., Balducci, A., ... & Li, P. K. T. (2022). Patient-centred approaches for the management of unpleasant symptoms in kidney disease. *Nature Reviews Nephrology*, 18(3), 185-198.
67. Katabathina, V. S., Menias, C. O., Khanna, L., Murphy, L., Dasyam, A. K., Lubner, M. G., & Prasad, S. R. (2019). Hereditary gastrointestinal cancer syndromes: role of imaging in screening, diagnosis, and management. *Radiographics*, 39(5), 1280-1301.
68. Kostine, M., Rouxel, L., Barnetche, T., Veillon, R., Martin, F., Dutriaux, C., ... & Schaefferbeke, T. (2018). Rheumatic disorders associated with immune checkpoint

- inhibitors in patients with cancer—clinical aspects and relationship with tumour response: a single-centre prospective cohort study. *Annals of the rheumatic diseases*, 77(3), 393-398.
69. Krueger, K. M., Ison, M. G., & Ghossein, C. (2020). Practical guide to vaccination in all stages of CKD, including patients treated by dialysis or kidney transplantation. *American Journal of Kidney Diseases*, 75(3), 417-425.
 70. Lahousse, A., Roose, E., Leysen, L., Yilmaz, S. T., Mostaqim, K., Reis, F., ... & Nijs, J. (2021). Lifestyle and pain following cancer: state-of-the-art and future directions. *Journal of clinical medicine*, 11(1), 195.
 71. Lam, G. A., Albarrak, H., McColl, C. J., Pizarro, A., Sanaka, H., Gomez-Nguyen, A., ... & Paes Batista da Silva, A. (2023). The oral-gut axis: periodontal diseases and gastrointestinal disorders. *Inflammatory bowel diseases*, 29(7), 1153-1164.
 72. Lameire, N. H., Levin, A., Kellum, J. A., Cheung, M., Jadoul, M., Winkelmayer, W. C., ... & Srisawat, N. (2021). Harmonizing acute and chronic kidney disease definition and classification: report of a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference. *Kidney international*, 100(3), 516-526.
 73. Larsson, S. C., & Burgess, S. (2021). Causal role of high body mass index in multiple chronic diseases: a systematic review and meta-analysis of Mendelian randomization studies. *BMC medicine*, 19, 1-10.
 74. Larsson, S. C., & Burgess, S. (2022). Appraising the causal role of smoking in multiple diseases: A systematic review and meta-analysis of Mendelian randomization studies. *EBioMedicine*, 82.
 75. Lee, P., Chandel, N. S., & Simon, M. C. (2020). Cellular adaptation to hypoxia through hypoxia inducible factors and beyond. *Nature reviews Molecular cell biology*, 21(5), 268-283.
 76. Lewis, R., Gómez Álvarez, C. B., Rayman, M., Lanham-New, S., Woolf, A., & Mobasheri, A. (2019). Strategies for optimising musculoskeletal health in the 21 st century. *BMC musculoskeletal disorders*, 20, 1-15.
 77. Liem, R. I., Lanzkron, S., D. Coates, T., DeCastro, L., Desai, A. A., Ataga, K. I., ... & Mustafa, R. A. (2019). American Society of Hematology 2019 guidelines for sickle cell disease: cardiopulmonary and kidney disease. *Blood advances*, 3(23), 3867-3897.
 78. Luan, X., Tian, X., Zhang, H., Huang, R., Li, N., Chen, P., & Wang, R. (2019). Exercise as a prescription for patients with various diseases. *Journal of sport and health science*, 8(5), 422-441.

79. Luttrell, T. (2024). Trauma and Inflammation of Soft Tissue: Rehabilitation and Wound Healing and Remodeling of Collagen. In *Foundations of Orthopedic Physical Therapy* (pp. 2-37). Routledge.
80. Mandras, S. A., Mehta, H. S., & Vaidya, A. (2020, September). Pulmonary hypertension: a brief guide for clinicians. In *Mayo Clinic Proceedings* (Vol. 95, No. 9, pp. 1978-1988). Elsevier.
81. Mannes, M., Schmidt, C. Q., Nilsson, B., Ekdahl, K. N., & Huber-Lang, M. (2021, December). Complement as driver of systemic inflammation and organ failure in trauma, burn, and sepsis. In *Seminars in immunopathology* (pp. 1-16). Springer Berlin Heidelberg.
82. Marotto, D., Atzeni, F., Ardizzone, S., Monteleone, G., Giorgi, V., & Sarzi-Puttini, P. (2020). Extra-intestinal manifestations of inflammatory bowel diseases. *Pharmacological Research*, 161, 105206.
83. Mata, R., Yao, Y., Cao, W., Ding, J., Zhou, T., Zhai, Z., & Gao, C. (2021). The dynamic inflammatory tissue microenvironment: Signaling and disease therapy by biomaterials. *Research*.
84. Meduri, G. U., & Chrousos, G. P. (2020). General adaptation in critical illness: glucocorticoid receptor-alpha master regulator of homeostatic corrections. *Frontiers in endocrinology*, 11, 161.
85. Meizlish, M. L., Franklin, R. A., Zhou, X., & Medzhitov, R. (2021). Tissue homeostasis and inflammation. *Annual review of immunology*, 39(1), 557-581.
86. Modi, Z. J., Lu, Y., Ji, N., Kapke, A., Selewski, D. T., Dietrich, X., ... & Gipson, D. S. (2019). Risk of cardiovascular disease and mortality in young adults with end-stage renal disease: an analysis of the US renal data system. *JAMA cardiology*, 4(4), 353-362.
87. Mullens, W., Damman, K., Testani, J. M., Martens, P., Mueller, C., Lassus, J., ... & Coats, A. (2020). Evaluation of kidney function throughout the heart failure trajectory—a position statement from the Heart Failure Association of the European Society of Cardiology. *European journal of heart failure*, 22(4), 584-603.
88. Murphey, M. D., & Kransdorf, M. J. (2021). Staging and classification of primary musculoskeletal bone and soft-tissue tumors according to the 2020 WHO update, from the AJR special series on cancer staging. *American Journal of Roentgenology*, 217(5), 1038-1052.
89. Nadim, M. K., Forni, L. G., Bihorac, A., Hobson, C., Koyner, J. L., Shaw, A., ... & Kellum, J. A. (2018). Cardiac and vascular surgery—associated acute kidney injury: the 20th

- international consensus conference of the ADQI (acute disease quality initiative) group. *Journal of the American Heart Association*, 7(11), e008834.
90. Naik, S., & Fuchs, E. (2022). Inflammatory memory and tissue adaptation in sickness and in health. *Nature*, 607(7918), 249-255.
 91. Nanchal, R., Subramanian, R., Karvellas, C. J., Hollenberg, S. M., Peppard, W. J., Singbartl, K., ... & Alhazzani, W. (2020). Guidelines for the management of adult acute and acute-on-chronic liver failure in the ICU: cardiovascular, endocrine, hematologic, pulmonary, and renal considerations. *Critical care medicine*, 48(3), e173-e191.
 92. Natoli, G., & Ostuni, R. (2019). Adaptation and memory in immune responses. *Nature immunology*, 20(7), 783-792.
 93. Ndumele, C. E., Rangaswami, J., Chow, S. L., Neeland, I. J., Tuttle, K. R., Khan, S. S., ... & American Heart Association. (2023). Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association. *Circulation*, 148(20), 1606-1635.
 94. Neag, M. A., Mocan, A., Echeverría, J., Pop, R. M., Bocsan, C. I., Crişan, G., & Buzoianu, A. D. (2018). Berberine: Botanical occurrence, traditional uses, extraction methods, and relevance in cardiovascular, metabolic, hepatic, and renal disorders. *Frontiers in pharmacology*, 9, 557.
 95. Neagu, M., Constantin, C., Popescu, I. D., Zipeto, D., Tzanakakis, G., Nikitovic, D., ... & Tsatsakis, A. M. (2019). Inflammation and metabolism in cancer cell—mitochondria key player. *Frontiers in Oncology*, 9, 348.
 96. Niec, R. E., Rudensky, A. Y., & Fuchs, E. (2021). Inflammatory adaptation in barrier tissues. *Cell*, 184(13), 3361-3375.
 97. Ogbechi, J., Clanchy, F. I., Huang, Y. S., Topping, L. M., Stone, T. W., & Williams, R. O. (2020). IDO activation, inflammation and musculoskeletal disease. *Experimental Gerontology*, 131, 110820.
 98. Oldroyd, A. G., Allard, A. B., Callen, J. P., Chinoy, H., Chung, L., Fiorentino, D., ... & Aggarwal, R. (2021). A systematic review and meta-analysis to inform cancer screening guidelines in idiopathic inflammatory myopathies. *Rheumatology*, 60(6), 2615-2628.
 99. Oliveira, C. B., Maher, C. G., Franco, M. R., Kamper, S. J., Williams, C. M., Silva, F. G., & Pinto, R. Z. (2020). Co-occurrence of chronic musculoskeletal pain and cardiovascular diseases: a systematic review with meta-analysis. *Pain Medicine*, 21(6), 1106-1121.
 100. Ostermann, M., Bellomo, R., Burdmann, E. A., Doi, K., Endre, Z. H., Goldstein, S. L., ... & Zarbock, A. (2020). Controversies in acute kidney injury: conclusions from a Kidney

- Disease: Improving Global Outcomes (KDIGO) Conference. *Kidney international*, 98(2), 294-309.
101. Palmer, W., Bancroft, L., Bonar, F., Choi, J. A., Cotten, A., Griffith, J. F., ... & Pfirmann, C. W. (2020). Glossary of terms for musculoskeletal radiology. *Skeletal radiology*, 49, 1-33.
 102. Paolino, S., Pacini, G., Patanè, M., Alessandri, E., Cattelan, F., Goegan, F., ... & Cutolo, M. (2019). Interactions between microbiota, diet/nutrients and immune/inflammatory response in rheumatic diseases: focus on rheumatoid arthritis. *Reumatologia/Rheumatology*, 57(3), 151-157.
 103. Pawa, S., Banerjee, P., Kothari, S., D'Souza, S. L., Martindale, S. L., Gaidos, J. K., ... & Burke, C. A. (2021). Are all endoscopy-related musculoskeletal injuries created equal? Results of a national gender-based survey. *Official journal of the American College of Gastroenterology| ACG*, 116(3), 530-538.
 104. Pearson, G. J., Thanassoulis, G., Anderson, T. J., Barry, A. R., Couture, P., Dayan, N., ... & Wray, W. (2021). 2021 Canadian Cardiovascular Society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in adults. *Canadian journal of cardiology*, 37(8), 1129-1150.
 105. Peiseler, M., Schwabe, R., Hampe, J., Kubes, P., Heikenwälder, M., & Tacke, F. (2022). Immune mechanisms linking metabolic injury to inflammation and fibrosis in fatty liver disease—novel insights into cellular communication circuits. *Journal of hepatology*, 77(4), 1136-1160.
 106. Platz, E., Jhund, P. S., Girerd, N., Pivetta, E., McMurray, J. J., Peacock, W. F., ... & Study Group on Acute Heart Failure of the Acute Cardiovascular Care Association and the Heart Failure Association of the European Society of Cardiology. (2019). Expert consensus document: reporting checklist for quantification of pulmonary congestion by lung ultrasound in heart failure. *European journal of heart failure*, 21(7), 844-851.
 107. Qu, F., Guilak, F., & Mauck, R. L. (2019). Cell migration: implications for repair and regeneration in joint disease. *Nature Reviews Rheumatology*, 15(3), 167-179.
 108. Rajendran, P., Chen, Y. F., Chen, Y. F., Chung, L. C., Tamilselvi, S., Shen, C. Y., ... & Huang, C. Y. (2018). The multifaceted link between inflammation and human diseases. *Journal of cellular physiology*, 233(9), 6458-6471.
 109. Ranasinghe, R., Mathai, M., & Zulli, A. (2022). A synopsis of modern-day colorectal cancer: Where we stand. *Biochimica et Biophysica Acta (BBA)-Reviews on Cancer*, 1877(2), 188699.

110. Rangaswami, J., Bhalla, V., Blair, J. E., Chang, T. I., Costa, S., Lentine, K. L., ... & American Heart Association Council on the Kidney in Cardiovascular Disease and Council on Clinical Cardiology. (2019). Cardiorenal syndrome: classification, pathophysiology, diagnosis, and treatment strategies: a scientific statement from the American Heart Association. *Circulation*, 139(16), e840-e878.
111. Renzi, C., Kaushal, A., Emery, J., Hamilton, W., Neal, R. D., Rachet, B., ... & Lyratzopoulos, G. (2019). Comorbid chronic diseases and cancer diagnosis: disease-specific effects and underlying mechanisms. *Nature reviews clinical oncology*, 16(12), 746-761.
112. Reyes-Hinojosa, D., Lozada-Pérez, C. A., Cuevas, Y. Z., López-Reyes, A., Martínez-Nava, G., Fernández-Torres, J., ... & Martínez-Flores, K. (2019). Toxicity of cadmium in musculoskeletal diseases. *Environmental Toxicology and Pharmacology*, 72, 103219.
113. Ribaldone, D. G., Pellicano, R., & Actis, G. C. (2019). The gut and the Inflammatory Bowel Diseases inside-out: The extra-intestinal manifestations. *Minerva gastroenterologica e dietologica*, 309-318.
114. Rivera-Izquierdo, M., Cabeza, L., Láinez-Ramos-Bossini, A., Quesada, R., Perazzoli, G., Alvarez, P., ... & Melguizo, C. (2019). An updated review of adipose derived-mesenchymal stem cells and their applications in musculoskeletal disorders. *Expert Opinion on Biological Therapy*, 19(3), 233-248.
115. Rosenstock, J., Perkovic, V., Johansen, O. E., Cooper, M. E., Kahn, S. E., Marx, N., ... & Carmelina Investigators. (2019). Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial. *Jama*, 321(1), 69-79.
116. Rossi, F., Tortora, C., Paoletta, M., Marrapodi, M. M., Argenziano, M., Di Paola, A., ... & Iolascon, G. (2022). Osteoporosis in childhood cancer survivors: physiopathology, prevention, therapy and future perspectives. *Cancers*, 14(18), 4349.
117. Ryan, A. M., & Sullivan, E. S. (2021). Impact of musculoskeletal degradation on cancer outcomes and strategies for management in clinical practice. *Proceedings of the Nutrition Society*, 80(1), 73-91.
118. Sange, A. H., Srinivas, N., Sarnaik, M. K., Modi, S., Pisipati, Y., Vaidya, S., ... & Sange, I. (2021). Extra-intestinal manifestations of inflammatory bowel disease. *Cureus*, 13(8).
119. Sardu, C., Gambardella, J., Morelli, M. B., Wang, X., Marfella, R., & Santulli, G. (2020). Hypertension, thrombosis, kidney failure, and diabetes: is COVID-19 an endothelial disease? A comprehensive evaluation of clinical and basic evidence. *Journal of clinical medicine*, 9(5), 1417.

120. Sarnak, M. J., Amann, K., Bangalore, S., Cavalcante, J. L., Charytan, D. M., Craig, J. C., ... & Conference Participants. (2019). Chronic kidney disease and coronary artery disease: JACC state-of-the-art review. *Journal of the American College of Cardiology*, 74(14), 1823-1838.
121. Savira, F., Magaye, R., Liew, D., Reid, C., Kelly, D. J., Kompa, A. R., ... & Wang, B. H. (2020). Cardiorenal syndrome: Multi-organ dysfunction involving the heart, kidney and vasculature. *British journal of pharmacology*, 177(13), 2906-2922.
122. Schieda, N., Blauchman, J. I., Costa, A. F., Glikstein, R., Hurrell, C., James, M., ... & Hiremath, S. (2018). Gadolinium-based contrast agents in kidney disease: a comprehensive review and clinical practice guideline issued by the Canadian Association of Radiologists. *Canadian journal of kidney health and disease*, 5, 2054358118778573.
123. Serhan, C. N., Gupta, S. K., Perretti, M., Godson, C., Brennan, E., Li, Y., ... & Wolkenhauer, O. (2020). The atlas of inflammation resolution (AIR). *Molecular aspects of medicine*, 74, 100894.
124. Sharma, A., Zhao, X., Hammill, B. G., Hernandez, A. F., Fonarow, G. C., Felker, G. M., ... & DeVore, A. D. (2018). Trends in noncardiovascular comorbidities among patients hospitalized for heart failure: insights from the get with the guidelines–heart failure registry. *Circulation: Heart Failure*, 11(6), e004646.
125. Silveira, E. A., da Silva Filho, R. R., Spexoto, M. C. B., Haghighatdoost, F., Sarrafzadegan, N., & de Oliveira, C. (2021). The role of sarcopenic obesity in cancer and cardiovascular disease: a synthesis of the evidence on pathophysiological aspects and clinical implications. *International journal of molecular sciences*, 22(9), 4339.
126. Song, Y., Wu, Z., & Zhao, P. (2022). The function of metformin in aging-related musculoskeletal disorders. *Frontiers in Pharmacology*, 13, 865524.
127. Stout, K. K., Daniels, C. J., Aboulhosn, J. A., Bozkurt, B., Broberg, C. S., Colman, J. M., ... & Van Hare, G. F. (2019). 2018 AHA/ACC guideline for the management of adults with congenital heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Journal of the American College of Cardiology*, 73(12), 1494-1563.
128. Stout, K. K., Daniels, C. J., Aboulhosn, J. A., Bozkurt, B., Broberg, C. S., Colman, J. M., ... & Van Hare, G. F. (2019). 2018 AHA/ACC guideline for the management of adults with congenital heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Journal of the American College of Cardiology*, 73(12), e81-e192.

129. Sturgeon, K. M., Mathis, K. M., Rogers, C. J., Schmitz, K. H., & Waning, D. L. (2019). Cancer-and chemotherapy-induced musculoskeletal degradation. *JBMR plus*, 3(3), e10187.
130. Suzuki, K. (2019). Chronic inflammation as an immunological abnormality and effectiveness of exercise. *Biomolecules*, 9(6), 223.
131. Tsutsui, H., Isobe, M., Ito, H., Okumura, K., Ono, M., Kitakaze, M., ... & Yamashina, A. (2019). JCS 2017/JHFS 2017 guideline on diagnosis and treatment of acute and chronic heart failure—digest version—. *Circulation Journal*, 83(10), 2084-2184.
132. Tucker-Bartley, A., Lemme, J., Gomez-Morad, A., Shah, N., Veliu, M., Birklein, F., ... & Upadhyay, J. (2021). Pain phenotypes in rare musculoskeletal and neuromuscular diseases. *Neuroscience & Biobehavioral Reviews*, 124, 267-290.
133. Turakhia, M. P., Blankestijn, P. J., Carrero, J. J., Clase, C. M., Deo, R., Herzog, C. A., ... & Wanner, C. (2018). Chronic kidney disease and arrhythmias: conclusions from a kidney disease: improving global outcomes (KDIGO) controversies conference. *European heart journal*, 39(24), 2314-2325.
134. Vaduganathan, M., Mensah, G. A., Turco, J. V., Fuster, V., & Roth, G. A. (2022). The global burden of cardiovascular diseases and risk: a compass for future health. *Journal of the American College of Cardiology*, 80(25), 2361-2371.
135. VanWagner, L. B., Harinstein, M. E., Runo, J. R., Darling, C., Serper, M., Hall, S., ... & Hammel, L. L. (2018). Multidisciplinary approach to cardiac and pulmonary vascular disease risk assessment in liver transplantation: an evaluation of the evidence and consensus recommendations. *American Journal of Transplantation*, 18(1), 30-42.
136. Varela, M. L., Mogildea, M., Moreno, I., & Lopes, A. (2018). Acute inflammation and metabolism. *Inflammation*, 41, 1115-1127.
137. Vasconcelos, D. P., Águas, A. P., Barbosa, M. A., Pelegrín, P., & Barbosa, J. N. (2019). The inflammasome in host response to biomaterials: Bridging inflammation and tissue regeneration. *Acta biomaterialia*, 83, 1-12.
138. Villeneuve, D. L., Landesmann, B., Allavena, P., Ashley, N., Bal-Price, A., Corsini, E., ... & Tschudi-Monnet, F. (2018). Representing the process of inflammation as key events in adverse outcome pathways. *Toxicological sciences*, 163(2), 346-352.
139. Weiskirchen, R., Weiskirchen, S., & Tacke, F. (2019). Organ and tissue fibrosis: Molecular signals, cellular mechanisms and translational implications. *Molecular aspects of medicine*, 65, 2-15.
140. Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., ... & Wright, J. T. (2018). 2017

- ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Journal of the American College of Cardiology*, 71(19), e127-e248.
141. Wiles, K., Chappell, L., Clark, K., Elman, L., Hall, M., Lightstone, L., ... & Bramham, K. (2019). Clinical practice guideline on
 142. Wong, S. K., Chin, K. Y., & Ima-Nirwana, S. (2020). Berberine and musculoskeletal disorders: the therapeutic potential and underlying molecular mechanisms. *Phytomedicine*, 73, 152892.
 143. Yang, Y. J., & Kim, D. J. (2021). An overview of the molecular mechanisms contributing to musculoskeletal disorders in chronic liver disease: osteoporosis, sarcopenia, and osteoporotic sarcopenia. *International journal of molecular sciences*, 22(5), 2604.
 144. Zanelli, M., Pizzi, M., Sanguedolce, F., Zizzo, M., Palicelli, A., Soriano, A., ... & Ascani, S. (2021). Gastrointestinal manifestations in systemic mastocytosis: the need of a multidisciplinary approach. *Cancers*, 13(13), 3316.
 145. Zhang, Q., & Cao, X. (2021). Epigenetic remodeling in innate immunity and inflammation. *Annual review of immunology*, 39(1), 279-311.
 146. Zhang, S., Miller, D. D., & Li, W. (2021). Non-musculoskeletal benefits of vitamin D beyond the musculoskeletal system. *International journal of molecular sciences*, 22(4), 2128.
 147. Zhang, S., Xing, M., & Li, B. (2019). Recent advances in musculoskeletal local drug delivery. *Acta biomaterialia*, 93, 135-151.
 148. Zhao, H. M., Xie, Y. X., Wang, C., Chinese Association of Rehabilitation Medicine, Respiratory Rehabilitation Committee of Chinese Association of Rehabilitation Medicine, & Cardiopulmonary Rehabilitation Group of Chinese Society of Physical Medicine and Rehabilitation. (2020). Recommendations for respiratory rehabilitation in adults with coronavirus disease 2019. *Chinese medical journal*, 133(13), 1595-1602.
 149. Ziade, N., El Khoury, B., Zoghbi, M., Merheb, G., Abi Karam, G., Mroue', K., & Messaykeh, J. (2020). Prevalence and pattern of comorbidities in chronic rheumatic and musculoskeletal diseases: the COMORD study. *Scientific reports*, 10(1), 7683.
 150. Zügel, M., Maganaris, C. N., Wilke, J., Jurkat-Rott, K., Klingler, W., Wearing, S. C., ... & Hodges, P. W. (2018). Fascial tissue research in sports medicine: from molecules to tissue diagnostics: consensus statement. *British journal of sports medicine*, 52(23), 1497-1497.